**Evolutionary Designs for Laryngeal Instrumentation**

Endocraft introduces the Universal Modular Subglottiscope & Universal Modular Slim Glottiscope, which have 3 sizes of Titanium Speculums. These new laryngoscopes join the Universal Modular Glottiscope & the Laryngoscopic Suspension Gallows to enhance microlaryngoscopic surgery by accommodating a spectrum of laryngeal anatomy, irrespective of gender, age or disease.

**Design Features**

- All Endocraft’s laryngoscopes have wide proximal bilateral slots, which is unlike virtually all other microscope-compatible tubular laryngoscopes that widen the proximal lumen to accommodate the convergence of microscope oculars. This feature enhances placement of larger-lumen speculums for high-power stereoscopic viewing of the surgical field. The slots also facilitate tangential angulation of hand instruments & laser fibers as well as easier insertion from the assistant.
- The new Laryngoscopes are compatible with Endocraft’s Laryngoscopic Suspension Gallows as well as American & European chest-support holders/stabilizers.
- Endocraft’s Glottiscopes are specially engineered to optimally expose the anterior commissure and can be used with the mirror-guided CO₂ laser as well as fiber-based laser systems.
- All Endocraft’s laryngoscopes are specially designed with a baseplate that inserts to varying positions & all have in-vivo removable cannulas for light, suction & jet ventilation.
- The detachable baseplates are a key feature of the Slim Glottiscope & Subglottiscope facilitating difficult intubations in complex airways with tumors and/or stenosis.
- The Subglottiscope is uniquely designed to accommodate the cartilage exoskeleton & airway conformation of the upper & lower (thyroid & cricoid cartilage) subglottic anatomy.

Endocraft Website: https://www.endocraftllc.com/  
E-mail: info@endocraft-llc.com 
Endocraft: Phone: (401) 369-7344, Fax: (401) 228-7397 
MADE IN THE UNITED STATES OF AMERICA
April 2021
Volume 40, No. 3

The Bulletin (ISSN 0731-8359) is published 11 times per year (with a combined December/January issue) by the American Academy of Otolaryngology–Head and Neck Surgery 1650 Diagonal Road, Alexandria, VA 22314-2857. Telephone: 1-703-836-4444. Member toll-free telephone: 1-877-722-6467. The Bulletin publishes news and opinion articles from contributing authors as a service to our readers. The views expressed in these articles are solely those of the individual and may or may not be shared by the AAO-HNS. Acceptance of advertising in the Bulletin in no way constitutes approval or endorsement by AAO-HNS of products or services advertised unless indicated as such.

President
Carol R. Bradford, MD, MS
Executive Vice President, CEO, and Editor of the Bulletin
James C. Denneny III, MD
Managing Editor
Tina Maggio
bulletin@entnet.org

INQUIRIES AND SUBMISSIONS
bulletin@entnet.org

MAILING INFORMATION
Postmaster: Send address changes to the American Academy of Otolaryngology–Head and Neck Surgery, 1650 Diagonal Road, Alexandria, VA 22314-2857.
Return undeliverable Canadian addresses to PO Box 503, RPO West Beaver Creek, Richmond Hill, Ontario, Canada L4B 4R6.
Publications Mail Agreement NO. 40721518

©2021 American Academy of Otolaryngology–Head and Neck Surgery

BULLETIN ADVERTISING
Ascend Media LLC
Suze Dittberner
7717 W. 95th St., Suite 300
Overland Park, KS 66222
Phone: 1-913-344-1420
Fax: 1-913-344-1492
sdittberner@ascendmedia.com

ADVERTISEMENT INDEX
Compulink Cover Tip, Back Cover
Endocraft Inside Front Cover
The Doctor’s Management Company 2
ASCENT 4
Otolaryngology–Head and Neck Surgery Call for Papers 8
AAO-HNSF 125 Strong Campaign 10
AAO-HNSF 2021 Annual Meeting & OTO Experience 11
Sanofi Insert, 21-22

This advertiser index is for reader convenience only and is not part of the advertising agreement. While every attempt is made to ensure accuracy, publisher cannot be held responsible for errors or omissions.

World Voice Day
ONE WORLD
MANY VOICES

CPG
CLINICAL PRACTICE GUIDELINE
Opioid Prescribing for Analgesia After Common Otolaryngology Operations

Candidates’ Statements

SECTION SPOTLIGHT: SRF
Expanding Resident Education through a Pandemic and Beyond

Match Day 2021

PEARLS FROM YOUR PEERS
Dermal Filler Complications

SPOTLIGHT: HUMANITARIAN EFFORTS
Miriam I. Redleaf, MD

FROM THE EDUCATION COMMITTEES
Tracheostomy Care

OUT OF COMMITTEE: PATIENT SAFETY AND QUALITY IMPROVEMENT
Improving Safety by Studying Why Things Go Terribly Right

ENTEALTH FOR YOUR PATIENTS
Aspiration

The leading edge
Why the Power of Our Voice Matters
by Carol R. Bradford, MD, MS

Focusing on Our Strategy for Today Outlines Our Plans for the Future
by James C. Denneny III, MD

At the forefront

inside this issue
Tirelessly defending the practice of
GOOD MEDICINE.

We’re taking the mal out of malpractice insurance. By constantly looking ahead, we help our members anticipate issues before they can become problems. And should frivolous claims ever threaten their good name, we fight to win—both in and out of the courtroom. It’s a strategy made for your success that delivers malpractice insurance without the mal. See how at thedoctors.com
Why the Power of Our Voice Matters

“The human voice is the most perfect instrument of all.”

— Arvo Part

As otolaryngologists, we know better than anyone how critically important the human voice is.

Patients with a wide range of throat ailments—from throat cancer to a crushed larynx—expect us to preserve their voices. We approach the vocal tract with extreme caution and delicate dexterity to ensure that patients are able to communicate verbally following surgery and other interventions.

And as World Voice Day approaches, our profession comes together to encourage our patients to assess their vocal health and take steps to take care of their voices.

But have you ever noticed that we sometimes fail to recognize the power of our own voices? Do we find our voices when we see or hear something that is not aligned with our core purpose and guiding principles? Do we speak up when a member of our community is not treated equitably? Are we using our voices to advocate for our patients and our practices? Are we asking questions at the conclusion of an education session when the learning objectives are not clear?

There are times when we know there is more to be said and heard.

As they say, the silence can be deafening.

Now, more than ever, we encourage our members to speak up and be heard. As we update our strategic plan, this is a critical time for our future. The more ideas we hear and different perspectives we consider, the greater the chances we will realize our vision together.

Actor Maggie Smith once said, “Speak your mind, even if your voice shakes.” I challenge you to be bold, to find your voice, and to use it for the betterment of our organization and society at large. We are all experts in something, and we are stronger when you share your knowledge, ideas, and perspectives.

In a large organization such ours, there are times when you might feel your voice is not heard. I urge you to keep trying, as our goal is to ensure that not only is your voice heard, but also that your voice speaks for the future of the American Academy of Otolaryngology–Head and Neck Surgery.

There are many avenues where you can share, including committees, meetings, conferences, and elections. In fact, the election for positions on the Academy’s Board of Directors is right around the corner. I encourage you to read the candidates’ statements, starting on page 24, then cast your vote when the election opens on May 3. Let your voice be heard as we select our future leaders.

Thank you for your voice and for your contributions to our collective future as an Academy.

Carol R. Bradford, MD, MS
AAO-HNS/F President

“I challenge you to be bold, to find your voice, and to use it for the betterment of our organization and society at large.”

— Carol R. Bradford, MD, MS
ASCENT
ADMINISTRATOR SUPPORT COMMUNITY for ENT
Otolaryngology Resource Network

DID YOU KNOW...

Membership in ASCENT provides the following resources so your manager/administrator doesn’t have to start from scratch. Some of our resources include:

- More than 3,000 policies/procedures, booklets, plans and customizable forms.
- Discounts on webinars, training modules, annual trainings, and more.
- The Certification in Otolaryngology Practice Management (COPM), which certifies your administrative leadership’s competence and dedication to the profession.
- Member-only discussion forums that are the perfect place for knowledge exchange, content, idea incubation and professional networking with fellow practice managers.
- Communities by practice size so that the administrator can network with similar sized practices.
- Weekly ENT-specific communications packed with association, ENT news, and legislative updates to keep you updated on the business management of your practice.
- Discounted member pricing to the ASCENT Annual Educational Conference.

Ask about our group membership options for multiple people in your practice. We also have a joint AAO-HNS/ASCENT membership option for administrators.

For less than a $1 per day, you, your administrator/manager can get the inside knowledge needed to keep on top of the otolaryngology practice today.

Find out more at www.askascent.org/join
As we enter the second quarter of 2021, it becomes clear that really nothing will be clear in healthcare for the rest of this year on many fronts. Both government and private payers continue to mandate additional requirements related to quality and payment. The COVID-19 pandemic has unleashed a flurry of scope of practice expansions at the state and national level, including the Veterans Administration hospitals. The short-term gains touted as a “great victory” for limiting surgical cuts only succeeded in delaying them and, as things stand now, putting otolaryngologists in a worse position than we would have been without the Consolidated Appropriations Act, 2021. We are now facing resumption of the 2% sequestration through the end of 2021 and an additional 4% sequestration starting in January 2022 courtesy of the recently passed $1.9 trillion COVID-19 relief bill. There is also concern that inpatient E/M CPT codes will be increased in the proposed rule this year, which will further reduce the value of surgical procedures. This will also include the loss of the “G” code that was to be used as an add-on for complex E/M services and expected to be utilized for at least 50% of otolaryngology E/M services.

The recent AAO-HNS/F strategic planning process identified a high priority need for expanded “business of medicine” services within the Academy. We will be further developing our advocacy staff with two new directors, including one to specifically deal with private payer and health policy issues. As the volume and complexity of these problems grow, this will be a significant addition to services we can provide for our members. This year, just as in the past several years, it will be critical to identify the appropriate partners for each of the issues facing us. They will not necessarily be the same ones for every issue as there is considerable disagreement within the house of medicine on many of them. One of the great opportunities we hope to take advantage of is the willingness of many of the large private payers to listen to suggestions that would standardize indications, coverage decisions, and documentation requirements. We are currently working with the American Rhinologic Society on standardizing imaging requirements related to chronic rhinosinusitis for presentation to multiple insurance companies. If this is successful, we can expand to other areas in the specialty. This would save the insurers, patients, and physicians both time and resources and result in an improvement in the “wellness factor” in dealing with so many disparate rules.

The emergence from the COVID-19 cloud will certainly bring about a number of changes in the way otolaryngologists practice, both in the clinic setting and the operating room. The Bulletin will have regular features on the many aspects of the “new normal” as it emerges. One of the first areas we will be exploring is what PPE will look like in our offices and surgery in the post-COVID era. The Future of Otolaryngology Task Force and the Patient Safety and Quality Improvement Committee will lead that effort, which will be followed with a special presentation at the Annual Meeting in Los Angeles, California. What will the telehealth world look like for otolaryngologists in practice as well as in teaching situations? Will the expansion of allied health provider’s privileges return to pre-pandemic levels or continue to expand? How will the over-the-counter availability of hearing aids change the hearing healthcare landscape? These are but a few of the many questions that will need to be answered sooner than later.

In addition to allocating more resources to address the advocacy issues listed above, we are also expanding our offerings related to “Wellness and Resiliency” as the problem continues to surge through and following the pandemic. The additional stresses that will result from system reform will be additive. The strategic planning process also identified this area as a high priority, and we will be adding a new position that will focus on wellness initiatives for our members.

The key to success over the next several years will be greatly impacted by our ability to execute the Five Fs. We must be familiar with the issues affecting us, find the ones where we can make a difference and develop a plan, have flexibility in how we tackle the problem, work with friends who have like issues, and finish strong with data-driven solutions.
Looking Ahead: May Is Better Hearing and Speech Month

**Hearing Loss with the Use of Protective Face Masks** offers tips to help maximize the ability to hear when someone is wearing a face mask or covering.

**How Can I Lessen the Impact of Tinnitus?** offers tips for reducing the impact of tinnitus and answers some frequently asked questions.
https://www.enthealth.org/be_ent_smart/how-can-i-lessen-the-impact-of-tinnitus/

**Speech and Language Development** is gleaned from the AAO-HNSF Clinical Practice Guideline (update): Otitis Media with Effusion, which offers patient friendly information for caregivers when Otitis Media with Effusion affects speech and language development.
https://www.enthealth.org/be_ent_smart/speech-and-language-development/

For more patient information, search the ENThealth.org library of content of Conditions and Treatments and Be ENT Smart articles by using keyword searches “hearing” and “speech.”

ENThealth.org is dedicated to helping patients. The content is developed from a team of AAO-HNS members, and information is delivered via peer-reviewed articles, interactive features, and video content featuring physicians. Learn more about the site and our contributors at https://www.enthealth.org/about-us/.

---

### 1903

Transactions from the Annual Meetings in 1896 and 1897 were collected, preserved, and disseminated. Beginning in 1903, these papers were released in a bound, hardcover collection as *The Transactions of the American Academy of Ophthalmology and Oto-Laryngology*.

### 1975

Transactions was separated into two publications, one for ophthalmology and one for otolaryngology.

### 1977

The otolaryngology version was retitled to *Otolaryngology*.

### 2021 International Visiting Scholarship

Are you an international otolaryngologist-head and neck surgeon, less than 40 years old or within the first eight years of professional practice after residency or fellowship training, and in a junior full-time teaching position? You may be eligible for a Virtual International Visiting Scholarship or International Visiting Scholarship (dependent on ability to obtain in-person observership).

The application deadline is May 1. Visit [www.entnet.org/IVS](http://www.entnet.org/IVS) or contact [international@entnet.org](mailto:international@entnet.org) for more information. Applications and supporting information must be submitted as a PDF to [international@entnet.org](mailto:international@entnet.org).
WIO Day 2021 Celebrations

WIO Day was held on March 8 in conjunction with International Women’s Day, which is a global day celebrating the social, economic, cultural, and political achievements of women. Here are a few ways the occasion was commemorated in 2021. For more social media activity, search #WomenInOtolaryngology.

HUMANITARIAN TRAVEL GRANT
Medical Mission in Phnom Phen, Cambodia

In January 2020, Jonnay Y. Ostrom, MD, and Sarah R. Akkina, MD, MS, traveled with a team of volunteers from Northwest Medical Volunteers and Face to Face to Phnom Phen, Cambodia, to provide care to patients with congenital, traumatic, and neoplastic face deformities. This mission has been ongoing since 2006 when it was started by Seattle, Washington, otolaryngologist Craig S. Murakami, MD, and Cambodian plastic surgeon Theavy Mok, MD. The focus of these humanitarian missions is to provide care in the form of microtia repair, cleft lip and palate repair, complex facial reconstruction, and head and neck cancer surgeries that would otherwise not be available.

In addition to helping patients who would not have access to such procedures, volunteers work closely with local physicians and residents from the Cambodian medical schools. A significant goal of the mission trip is to provide lectures, conduct one-on-one teaching, and operate side by side with Cambodian medical students and physicians.

Patients come from all over Cambodia and sometimes wait for days to be evaluated for a potential surgery.

The Soviet Friendship Hospital becomes their home while they wait for their operations and recover before starting the journey home. Historically the mission has been completed once per year, but the number of patients presenting for evaluation continues to rise. Northwest Medical Volunteers, therefore, hopes to increase the frequency of trips to Cambodia in the future to further offset the reconstructive needs of the Khmer people.

READ MORE ONLINE
Longer article available

WIO Day 2021 Celebrations

WIO Day was held on March 8 in conjunction with International Women’s Day, which is a global day celebrating the social, economic, cultural, and political achievements of women. Here are a few ways the occasion was commemorated in 2021. For more social media activity, search #WomenInOtolaryngology.

HUMANITARIAN TRAVEL GRANT
Medical Mission in Phnom Phen, Cambodia

In January 2020, Jonnay Y. Ostrom, MD, and Sarah R. Akkina, MD, MS, traveled with a team of volunteers from Northwest Medical Volunteers and Face to Face to Phnom Phen, Cambodia, to provide care to patients with congenital, traumatic, and neoplastic face deformities. This mission has been ongoing since 2006 when it was started by Seattle, Washington, otolaryngologist Craig S. Murakami, MD, and Cambodian plastic surgeon Theavy Mok, MD. The focus of these humanitarian missions is to provide care in the form of microtia repair, cleft lip and palate repair, complex facial reconstruction, and head and neck cancer surgeries that would otherwise not be available.

In addition to helping patients who would not have access to such procedures, volunteers work closely with local physicians and residents from the Cambodian medical schools. A significant goal of the mission trip is to provide lectures, conduct one-on-one teaching, and operate side by side with Cambodian medical students and physicians.

Patients come from all over Cambodia and sometimes wait for days to be evaluated for a potential surgery.

The Soviet Friendship Hospital becomes their home while they wait for their operations and recover before starting the journey home. Historically the mission has been completed once per year, but the number of patients presenting for evaluation continues to rise. Northwest Medical Volunteers, therefore, hopes to increase the frequency of trips to Cambodia in the future to further offset the reconstructive needs of the Khmer people.

READ MORE ONLINE
Longer article available
Expanding Resident Education through a Pandemic and Beyond

Chelsea S. Hamill, MD

I am serving as this year’s Society of University Otolaryngologists Head & Neck Surgeons (SUO) delegate for the American Academy of Otolaryngology–Head and Neck Surgery (AAO-HNS) Section for Residents and Fellows-in-Training. SUO has a yearly meeting combined with the Association of Academic Departments of Otolaryngology and the Otolaryngology Program Directors Organization, which was originally scheduled for this past November. However, due to the unprecedented year, online webinars were offered on a variety of topics throughout the year. This year’s online platform has shown me the immense collaboration and effort that goes into resident education. And the best part? It is available for all.

Although the pandemic challenged us in many ways, these webinars have shown that resident education is still a priority: from AAO-HNS bringing us new education platforms to the creation of multiple education consortiums. Researchers are investigating how residents are using these virtual learning opportunities during the pandemic and how they may incorporate these new formats into residency program curricula.

Not only have they been working hard for the current residents, they are also looking into the future. This was first introduced when discussing inclusion within otolaryngology, given that the specialty has one of the lowest percentages of women, Hispanic, and Black physicians among its members. Further discussions centered on incorporating these concepts within our resident education, normalizing these conversations within the workforce to push these agendas forward, and changing the recruitment process to increase diversity within otolaryngology.

While we are consciously changing the demographics of our future colleagues, we are also doing so in this new era without Step 1 scores. There are so many things to consider when reading an application. Thus, scientific programs are emerging to ensure that our future colleagues’ personalities are cohesive within our field and values allow them to be successful.

Although I’ve summarized many of the themes of this year’s discussions, I hope you can all see that our future colleagues are in good hands and encourage you all to listen to the webinars that are found online at https://suo-aado.org/mpage/pastwebinars2020.
AAO-HNS Welcomes the Class of 2021
Otolaryngology-Head and Neck Surgery Matches
#IAMOTO

Visit www.entnet.org/otomatch to see a compilation of the Match Day activity shared on Facebook, Twitter, and Instagram.
#MAKEOTOSTRONGER
Support the 125 Strong Campaign

Make your donation today to launch projects in four key program areas:

- **New** online donation form that allows you to donate from your mobile device using Venmo, Google Pay, and Apple Pay
- **Scan or text** your donation today by scanning the QR code below or texting 125 to 202-858-1233
- **#MakeOTOStronger** by showing your support through social media

DONATE TODAY
www.entnet.org/125Strong
REGISTRATION WILL OPEN
JUNE 2021

Join us in Los Angeles, California October 3-6, for the 125th Anniversary

Conference registration includes one-year access to OTO Logic with the opportunity to earn 300+ hours of CME credit

Introduction of the New ‘Personal and Professional Development’ specialty track

New features include the Great Debates, Simulation Activities, and ENTpreneur Face-Off

MONDAY, OCTOBER 4, AT CEDARS-SINAI
Worst Case Scenarios: Managing OTO Emergencies in Practice Simulation Workshop

MORE INFORMATION TO COME

www.entannualmeeting.org
I’m **Nina Lu, MD**, a facial plastic and reconstructive surgeon at the University of Washington. I’m joined by **Theda C. Kontis, MD**, a double board-certified facial plastic surgeon practicing in Baltimore, Maryland, and clinical associate professor at The Johns Hopkins Hospital.

**Dr. Lu:** There has been quite the media buzz around dermal fillers and the COVID-19 vaccine. The U.S. Food and Drug Administration reported a total of three patients with facial swelling related to dermal fillers in the Moderna COVID-19 vaccine trial. Although this topic has garnered recent media attention, delayed swelling with dermal fillers is a rare but previously described event seen with vaccinations, viral infections, and allergic reactions. What do you recommend patients do with dermal fillers and vaccinations?

**Dr. Kontis:** I have not changed my practice at all, and I recommend all patients get vaccinated as they are able. Currently, there isn’t enough data to conclude a definitive timeline or need for delay between dermal filler and vaccinations. Delayed swelling is a very rare complication, and the Moderna study did not detail the type of hyaluronic acid filler used or the total number of patients in the trial who received dermal filler. The symptoms resolve easily with minimal treatment and no long-term side effects. I inform my patients of the details of the trial, that the risk is very low, and have them contact me if they experience any issues. To date there have been about 23 million COVID-19 vaccines given,* and we are not hearing of increased incidences of facial swelling. In my practice many of my filler patients have had the vaccine and have not experienced any filler complications.

**Dr. Lu:** If delayed facial swelling does occur, what is your typical treatment regimen?

**Dr. Kontis:** I examine the patient, and if it is just soft tissue edema, I start them on an oral antihistamine or Medrol Dosepak depending on the severity. If the filler is very firm on palpation, I use Clarithromycin for three to four weeks. In recalcitrant cases I may consider an intradermal steroid injection, with or without 5-fluorouracil. Swelling typically resolves over the course of days to weeks.

**Dr. Lu:** The most devastating complication of dermal fillers is vascular occlusion. Luckily, this is very rare and avoidable by experienced injectors such as yourself. In the rare event that it does occur, what treatment regimen do you recommend?

**Dr. Kontis:** Recognition during the injection is the most important step. Skin blanching and pain are early warning signs, so stop injecting right away. I immediately place warm compresses and massage the area. If these maneuvers do not improve the blanched area, flood the pale area with hyaluronidase, apply topical nitro paste, and administer ASA 325. Most importantly, see the patient daily. Hyperbaric oxygen can be used for severe cases.

---

*This data is as of February 10, 2021, the date the article was submitted for publication.*
Where do you currently practice, and what is your specialty area?
I am an otologist/neurotologist and former tenured professor at the University of Illinois. Now, I am relocating to be in otology/neurotology and neurosurgery at the University of New Mexico.

What humanitarian organizations are you involved with, and describe what these programs do?
Our four adopted Ethiopian children are in their thirties now, and we have maintained close ties to the country. Since 2012 I have been discovering the infrastructure from which I and others developed education programs in Ethiopia through our charity called the Ethio-American Hearing Project. Some of the programs we provide include:

- Cued speech education in deaf schools
- Audiology training and development of audiology testing and treatment sites with the Eduplex Training Institute
- Otologic surgical training with six surgical (mostly university) sites
- Development of cochlear implantation in partnership with MED-EL
- Annual International Ethiopian Otology Conference (2020 canceled due to the COVID-19 pandemic)
- Parkinson’s boxing program

How does your work impact the communities you serve, and how does it impact you as a person?
I believe my work is worthwhile because we have trained five otologists in a country where there had only been one. Two more people are in training now, and two more are on deck to start. Furthermore, we trained 29 audiology technicians in a country where there were no audiologists and only one hearing aid specialist. And we have been able to create a cochlear implant program using only Ethiopian nationals for the work in a country with no audiologists and no otologists.

My motivation for my work is fairness. I think it’s only fair to share our education and get these Ethiopian colleagues on their feet.

What would you say to encourage others to support humanitarian efforts around the world?
My advice to other surgeons would be to put your ego aside and your hopes of operating without electronic medical record hassles and the elaborate obstacles in the United States—try to make the actual place you go to better. Of course we would all love to fly into a country and do 40 stapedectomies and then fly home knowing we helped 40 people hear better. But I strongly feel we have more of a duty to help the surgeons there do the 40 stapedectomies. A corollary to that principle would be that it’s probably best to always go to the same country.
World Voice Day April 16, 2021: ONE WORLD, MANY VOICES

Sid Khosla, MD,
Voice Committee member

The theme for this year’s World Voice Day (WVD) is “One World, Many Voices.” Given the many interpretations of the theme, our committee thought it was important to gather the thoughts of “many voices.” As you will see, the responses were as varied and beautiful as to be expected.

My own interpretation is as follows: One of the reasons I became a physician was to listen to people’s stories, not the everyday conversations, but the more intimate details often discussed in the patient-physician relationship. I have come to think of these details and stories as the inner voice, a collective representation of what the person has experienced, who they are, and who they want to be. As a laryngologist, I previously focused on the external voice, assuming that a patient’s inner voice has been established long before they met me. However, some of my patients have taught me otherwise, that changing the external voice can also influence the inner. I have found this to be especially true in my patients who cannot speak after laryngeal trauma. Because they have difficulty communicating, they often give up trying to express their opinions. They withdraw and the inner voice becomes faint and fluid. After reconstruction, I see their personality change. Their inner voice blossoms as they learn to speak up. I am lucky enough to participate in their beautiful transformations. However, this is not true just for out aphonic patients. As otolaryngologists, speech language pathologists, or other voice professionals, we often see the inner voice change as the outer one becomes clearer. When I think of the theme of this year’s WVD, it reminds me of our role as voice professionals and as citizens to encourage the expression of each person’s individual voice.

I have reflected upon the 2021 WVD theme since it was first chosen in fall of 2020, a year which is irrevocably linked to the coronavirus pandemic, social unrest, and political discord.

I like the theme; it feels good to say it. I do have this tendency sometimes to think a lot about things, really a lot, and this theme became one of those things.

The words “One World” strike me as having multiple interpretations. One is a literal sense of a single planet Earth. A more philosophical sense invokes images of solidarity and unity of purpose, or less favorably, images of toddlers or, sadly, adults screaming “mine, mine” and fighting over that one world.

The words “Many Voices” also bring to mind multiple images. There are the voices of a well-conducted ensemble, weaving together into harmonious music. The contrasting image of people shouting with a goal of drowning out other voices also comes to mind; discordant tones lacking synchrony or harmony.

So “One World, Many Voices” also bring to mind multiple images. There are the voices of a well-conducted ensemble, weaving together into harmonious music. The contrasting image of people shouting with a goal of drowning out other voices also comes to mind; discordant tones lacking synchrony or harmony.

Perhaps a good interpretation of this theme is actually: One World, Many Conversations? Yeah?

I kind of like that. Let’s think about that for a while.
to pay more attention to each other's voices and try to hear and understand each other better now. Our voices will be the most important tool in removing the barriers among us and bringing us all together despite our cultural, social, and economic differences. We have one world, and yet, we have many voices to sound, hear in order to make it a better place for living.

Hakan Birkent, MD
Istanbul, Turkey
In Turkey we celebrate World Voice Day by emphasizing the importance and beauty of the voice. Although we will carry out this year's activities in virtual environments, we aim to celebrate the World Voice Day activities next year simultaneously with the Voice Istanbul Meeting. May your voice always be good. I hope that the coming days will be better, and I wish everybody a happy World Voice Day with warm feelings from Turkey.

Gustavo P. Korn, MD
São Paulo, Brazil
On April 16, Brazil will celebrate the 22nd edition of the National Voice Campaign. The National Voice Campaign, a joint effort by the Brazilian Academy of Laryngology and Voice and the Brazilian Association of Otolaryngology-Head and Neck Surgery, lasts for one week including April 16. Since 2003 (after its founding in 1999), it has gained international recognition in the form of World Voice Day and currently, more than 100 countries have adopted the same date and symbol for World Voice Day. Since then, many services nationwide have voluntarily participated in editions, offering free care to citizens during Voice Week, focusing on early diagnosis of laryngeal cancer and detection of alterations, and speeding up the therapeutic approach.

Throughout these two decades, we have remained focused on the greater goal of the Voice Campaign, which uses guidance and awareness-raising activities to promote lasting awareness of voice care. Each year means another brick in the construction and creation of this alert message—prevention and therapeutics. Besides voluntary collaboration of prominent national public figures and open presentations like beat box battles, from 2010 to 2018, an inflatable giant larynx structure was developed—in reality a giant mouth-pharynx-larynx model—that visitors can enter and learn about the anatomy of the throat and how the voice is produced. Over the years, thousands of people including children have visited our inflatable model. Information about voice care was also presented in media.

Anais Rameau, MD, MPhil
New York, New York
Perhaps one of the most important facts revealed by this pandemic is that we all live as parts of the same whole on this beautiful planet, regardless of religion, language, race, and color. On these hard days, we all hear and understand the feelings and voices of other people living in different parts of the world since we all have become equal in the face of this global threat. This is exactly why we need
opioid use disorder (OUD), which includes misuse, abuse, and overdose of opioids, is an epidemic in the United States. According to data from the National Survey on Drug Use and Health, more than six million people ages 12 or older misuse prescription pain relievers every year in the United States. Additionally, studies have shown that there is a significant risk of chronic opioid use even when used as short-term treatment for pain.

“As otolaryngology-head and neck surgeons, we can help reduce the risk of OUD among our patients and their families. This CPG focuses on multimodal analgesia and judicious use of opioids for common otolaryngology procedures,” said Samantha Anne, MD, MS, Chair of the Guideline Development Group (GDG). James “Whit” Mims, MD, served as Assistant Chair, and David E. Tunkel, MD, and Richard M. Rosenfeld, MD, MPH, MBA, served as Methodologists.

The purpose of this specialty-specific guideline is to provide evidence-informed recommendations on postoperative management for pain in common otolaryngologic surgical procedures, with a focus on opioids.

In addition, it allows identification of quality improvement opportunities in postoperative pain management of common otolaryngologic surgical procedures. Employing the key action statements from this CPG can help to reduce the variation in care across the specialty and improve postoperative pain control while reducing the risk of OUD.

“Many times opioids are prescribed in large quantities for procedures that are associated with mild to moderate pain, such as parathyroidectomy, thyroidectomy, and otologic surgeries. The number of opioids prescribed for these procedures can be reduced, especially if appropriate multimodal analgesia is used,” says Dr. Anne. “The guideline also emphasizes the importance of counseling patients and identifying patient- and procedure-related factors that can inform shared decision-making.”

The guideline addresses assessment of patients for OUD risk factors, counseling on pain expectations, and identifying factors that can impact pain duration and/or severity. It also discusses the use of multimodal analgesia as first-line treatment and responsible use of opioids. Lastly, safe disposal of unused opioids is discussed.

The guideline reviews the healthcare burden caused by OUD. It highlights research on opioid prescribing and misuse in the U.S. as well as the mortality attributed to opioid overdoses. Additionally, it presents data on overprescribing of opioids for postoperative pain and the diversion of unused opioid medication.

**Guideline Key Action Statements (KASs)**

**KAS 1: Expected Pain (recommendation)**
Prior to surgery, clinicians should advise patients and others involved in the postoperative care about the expected duration and severity of pain.

**KAS 2: Modifying Factors (recommendation)**
Prior to surgery, clinicians should gather information specific to the patient that modifies severity and/or duration of pain.

**KAS 3A: Risk Factors for Opioid Use Disorder (strong recommendation)**
Prior to surgery, clinicians should identify risk factors for OUD when analgesia using opioids is anticipated.

**KAS 3B: Patients at Risk for Opioid Use Disorder (recommendation)**
In patients at risk for OUD, clinicians should evaluate the need to modify the analgesia plan.

**KAS 4: Shared Decision Making (recommendation)**
Clinicians should promote shared decision making by informing patients of the benefits and risks of postoperative pain treatments that include nonopioid analgesics, opioid analgesics, and nonpharmacologic interventions.

**KAS 5: Multimodal Therapy (recommendation)**
Clinicians should develop a multimodal treatment plan for managing postoperative pain.

**KAS 6: Nonopioid Analgesia (strong recommendation)**
Clinicians should advocate for nonopioid medications as first-line management of pain after otolaryngologic surgery.

**KAS 7: Opioid Prescribing (recommendation)**
When treating postoperative pain with opioids, clinicians should limit therapy to the lowest effective dose and the shortest duration.
KAS 8A: Patient Feedback (recommendation)
Clinicians should instruct patients and caregivers how to communicate if pain is not controlled or if medication side effects occur.

KAS 8B: Stopping Pain Medications (recommendation)
Clinicians should educate patients to stop opioids when pain is controlled with nonopioids and stop all analgesics when pain has resolved.

KAS 9: Storage and Disposal of Opioids (strong recommendation)
Clinicians should recommend that patients (or their caregivers) store prescribed opioids securely and dispose of unused opioids through take-back programs or another accepted method.

KAS 10: Assessment of Pain Control with Opioids (recommendation)
Clinicians should inquire, within 30 days of surgery, whether the patient has stopped using opioids, has disposition of unused opioids, and was satisfied with the pain management plan.

The GDG included 16 members representing otolaryngology-head and neck surgery generalists and subspecialists, pain management, nursing, and consumers. The CPG is intended for otolaryngologists who perform surgery and clinicians who manage pain after surgical procedures. The target patients for the guideline are any patients treated for anticipated or reported pain within the first 30 days after undergoing common otolaryngologic procedures.

The Opioid Prescribing for Analgesia After Common Otolaryngology Operations CPG was created using the methods listed in the AAO-HNSF “Clinical Practice Guideline Development Manual, Third Edition.”

The full guideline and other resources are available at www.entnet.org/opioidscpg and in Otolaryngology—Head and Neck Surgery as published at otojournal.org.

Guideline authors:
Samantha Anne, MD, MS (Chair); James W. Mims, MD (Assistant Chair); David E. Tunkel, MD (Methodologist); Richard M. Rosenfeld, MD, MPH, MBA (Methodologist); David S. Bossonneau, MD; Michael J. Brenner, MD; John D. Cramer, MD; David Dickerson, MD; Sandra A. Finestone, PsyD; Adam J. Folbe, MD, MS; Dee J. Galaya, MD; Anna H. Messner, MD; Allison Pasley, CNRN; Ahmad R. Sedaghat, MD, PhD; Kerstin M. Stenson, MD; Angela K. Sturm, MD; Erin M. Lambie, MS, MPH; Nui Dhyphasuwan, MEd; and Taskin M. Morjur.

Endorsed by:
American Academy of Facial Plastic and Reconstructive Surgery (AAFPRS); American Broncho-Esophageal Association (ABEA); American Head and Neck Society (AHNS); American Neurootology Society (ANS); American Otolaryngological Association (AOA); American Rhinologic Society (ARS); American Society of Pediatric Otolaryngology (ASPO); Society of Otolaryngology and Head-Neck Nurses (SOHN); The Triological Society

Disclaimer:
This guideline is not intended as the sole source of guidance in prescribing opioids and/or analgesics for common otolaryngologic procedures. Rather, it is designed to assist clinicians by providing an evidence-informed framework for decision-making strategies. The guideline is not intended to replace clinical judgment or establish a protocol for management for all individuals with pain after otolaryngologic surgery and may not provide the only appropriate approach to managing postoperative pain. As medical knowledge expands, and technology advances, clinical indicators and guidelines are promoted as conditional and provisional proposals of what is recommended under specific conditions but are not absolute. Guidelines are not mandates. They do not and should not purport to be a legal standard of care. The responsible physician, in light of all circumstances presented by the individual patient, must determine the appropriate treatment. Adherence to these guidelines will not ensure successful patient outcomes in every situation. The AAO-HNSF emphasizes that these clinical guidelines should not be deemed to include all proper treatment decisions or methods of care reasonably directed to obtaining the same results.

References:

Accompanying Resources:
• Plain Language Summary
• Executive Summary
• Slide deck
• Podcasts
• Patient handouts (in both English and Spanish)
• Official quick-reference pocket guide and app
• Video on safe storage and disposal of opioids

Access all of these resources and more at www.entnet.org/opioidscpg.
# CLINICAL PRACTICE GUIDELINES

## PATIENT INFORMATION

### FREQUENTLY ASKED QUESTIONS (FAQs) COMPARING NONOPIOID AND OPIOID MEDICATIONS

<table>
<thead>
<tr>
<th>Frequently Asked Questions</th>
<th>Opioids</th>
<th>Nonsteroidal Antiinflammatory Drugs (NSAIDs)</th>
<th>Acetaminophen</th>
<th>Gabapentinoids</th>
</tr>
</thead>
<tbody>
<tr>
<td>CAN I BE ADDICTED TO THIS?</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
<td>Yes</td>
</tr>
<tr>
<td>WHEN ARE THEY USED—WHAT LEVEL OF PAIN?</td>
<td>Severe pain</td>
<td>Mild - Severe</td>
<td>Mild - Severe</td>
<td>Mild - Moderate</td>
</tr>
<tr>
<td>SHOULD I START WITH THIS MEDICATION?</td>
<td>No, use only if around-the-clock nonopioid medications are not enough.</td>
<td>Yes, you may start with this medication.</td>
<td>Yes, you may start with this medication.</td>
<td>No, only use if NSAIDs and/or acetaminophen is not enough.</td>
</tr>
<tr>
<td>IS THIS USED ALONE OR WITH OTHER MEDICATIONS?</td>
<td>Should be used in combination with other pain medications.</td>
<td>Can be used alone or in combination.</td>
<td>Can be used alone or in combination.</td>
<td>Should be used in combination with other pain medications.</td>
</tr>
<tr>
<td>CAN I STOP USING THIS MEDICATION AND HOW DO I STOP?</td>
<td>Sometimes this needs to be slowly stopped (&quot;tapered&quot;) depending on how much you have taken. Talk about this with your health care provider.</td>
<td>This can be stopped at any time.</td>
<td>This can be stopped at any time.</td>
<td>Sometimes this needs to be slowly stopped (&quot;tapered&quot;) depending on how much you have taken. Talk about this with your health care provider.</td>
</tr>
</tbody>
</table>


---

**ABOUT THE AAO-HNS/F**

The American Academy of Otolaryngology-Head and Neck Surgery (AAO-HNS) represents approximately 12,000 specialists worldwide who treat the ear, nose, throat, and related structures of the head and neck. The AAO-HNS Foundation works to advance the art, science, and ethical practice of otolaryngology-head and neck surgery through education, research, and lifelong learning.
## Frequently Asked Questions (FAQs) Comparing Nonopioid and Opioid Medications

**About the AAO-HNS/F**

The American Academy of Otolaryngology-Head and Neck Surgery (AAO-HNS) represents approximately 12,000 specialists worldwide who treat the ear, nose, throat, and related structures of the head and neck. The AAO-HNS Foundation works to advance the art, science, and ethical practice of otolaryngology-head and neck surgery through education, research, and lifelong learning.

### WHAT ARE THE COMMON SIDE EFFECTS (REPORTED IN 3% OR MORE PATIENTS)?

<table>
<thead>
<tr>
<th>Frequently Asked Questions</th>
<th>Opioids</th>
<th>Nonsteroidal Antiinflammatory Drugs (NSAIDs)</th>
<th>Acetaminophen</th>
<th>Gabapentinoids</th>
</tr>
</thead>
<tbody>
<tr>
<td>WHAT ARE THE COMMON SIDE EFFECTS (REPORTED IN 3% OR MORE PATIENTS)?</td>
<td>Dizziness, nausea (very common), headache, drowsiness (feeling sleepy or tired), vomiting, dry mouth, itching, and constipation.</td>
<td>Upset stomach</td>
<td>Nausea, vomiting, headache, and insomnia (being unable to sleep).</td>
<td>Dizziness, drowsiness (feeling sleepy or tired), swelling in the hands and feet, weight gain, and blurred vision.</td>
</tr>
</tbody>
</table>

### WHAT ARE THE SERIOUS RISKS AND WHAT IS THE RISK OF ADDICTION OR DEPENDENCE?

<table>
<thead>
<tr>
<th>Frequently Asked Questions</th>
<th>Opioids</th>
<th>Nonsteroidal Antiinflammatory Drugs (NSAIDs)</th>
<th>Acetaminophen</th>
<th>Gabapentinoids</th>
</tr>
</thead>
<tbody>
<tr>
<td>WHAT ARE THE SERIOUS RISKS AND WHAT IS THE RISK OF ADDICTION OR DEPENDENCE?</td>
<td>Respiratory depression (very slow breathing), misuse, abuse, addiction, overdose, and death from respiratory depression. Your risk of opioid abuse increases the longer you take the medication.</td>
<td>Stomach bleeding or ulcers, heart attack, kidney damage, and stroke. Celecoxib has a lower risk of stomach bleeding and/or ulcer formation over the short term.</td>
<td>Liver damage may occur at high doses (greater than 3,000 milligrams in 24 hours).</td>
<td>Suicidal thoughts, respiratory depression. Suicidal thoughts, respiratory depression. Suicidal thoughts, respiratory depression. Suicidal thoughts, respiratory depression.</td>
</tr>
</tbody>
</table>

Adapted from the American College of Surgeons' patient education brochure on Safe and Effective Pain Control After Surgery.12

# Clinical Practice Guidelines

## Patient Information

### Frequently Asked Questions (FAQs) About Opioids

<table>
<thead>
<tr>
<th>Question</th>
<th>Answer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>When should I begin taking my opioid pain medication?</strong></td>
<td>Pain medication should be taken for severe pain as needed, but only if pain is not controlled with nonopioid medication (painkillers such as acetaminophen or ibuprofen). If you need opioids for severe pain, take them as prescribed on the medication's bottle.</td>
</tr>
<tr>
<td><strong>How many should I take at any given time?</strong></td>
<td>To figure out how many pills you should take, read the instructions on the medication's bottle or the instructions given to you by your health care provider.</td>
</tr>
<tr>
<td><strong>Can I take Tylenol, aspirin, or Advil instead of this medication or with this medication?</strong></td>
<td>Probably yes, but you should check with your health care provider. Some prescribed pain medications combine acetaminophen with opioids. Taking additional acetaminophen with the prescribed combination pain medication could be unsafe.</td>
</tr>
<tr>
<td><strong>Do I need to finish the entire bottle of pills?</strong></td>
<td>No, pain medication should be taken when needed and pain medication must be stopped when pain is controlled. If your severe pain is under control, there is no need to finish the bottle.</td>
</tr>
<tr>
<td><strong>What should I do with the pills that are leftover?</strong></td>
<td>Leftover pills should not be left in your home where someone else can take them. There are facilities that will take these leftover medications. Check with your health care provider.</td>
</tr>
<tr>
<td><strong>Can I give these pain medications to family members?</strong></td>
<td>No, medications should never be shared with a family member or anyone else. If you have any pills leftover, check with your health care provider or take them to a facility that will get rid of them safely.</td>
</tr>
</tbody>
</table>


---

**About the AAO-HNS/F**

The American Academy of Otolaryngology–Head and Neck Surgery (AAO-HNS) represents approximately 12,000 specialists worldwide who treat the ear, nose, throat, and related structures of the head and neck. The AAO-HNS Foundation works to advance the art, science, and ethical practice of otolaryngology–head and neck surgery through education, research, and lifelong learning.
DUPIXENT® (dupilumab) injection, for subcutaneous use Rx only

Brief Summary of Prescribing Information

1 INDICATIONS AND USAGE
1.3 Chronic Rhinosinusitis with Nasal Polyps
DUPIXENT is indicated as an add-on maintenance treatment in adult patients with inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP).

4 CONTRAINDICATIONS
DUPIXENT is contraindicated in patients who have known hypersensitivity to dupilumab or any of its excipients [see Warnings and Precautions (5.1)].

5 WARNINGS AND PRECAUTIONS
5.1 Hypersensitivity
Hypersensitivity reactions, including generalized urticaria, rash, erythema nodosum and serum sickness or serum sickness-like reactions, were reported in less than 1% of subjects who received DUPIXENT in clinical trials. If a clinically significant hypersensitivity reaction occurs, institute appropriate therapy and discontinue DUPIXENT [see Adverse Reactions (6.1, 6.2)].

5.2 Conjunctivitis and Keratitis
In subjects with CRSwNP, the frequency of conjunctivitis was 2% in the DUPIXENT group compared to 1% in the placebo group in the 24-week safety pool; these subjects recovered. There were no cases of keratitis reported in the CRSwNP development program [see Adverse Reactions (6.1)].

5.3 Eosinophilic Conditions
Patients being treated for asthma may present with serious systemic eosinophilic conditions presenting with clinical features of eosinophilic pneumonia or vasculitis consistent with eosinophilic granulomatosis with polyangiitis, conditions which are often treated with systemic corticosteroid therapy. These events may be associated with the reduction of oral corticosteroid therapy. Physicians should be alert to vasculitic rash, worsening pulmonary symptoms,cardiac complications, and/or neuropsychiatric presenting in their patients with eosinophilia. Cases of eosinophilic pneumonia were reported in adult patients who participated in the asthma development program and cases of vasculitis consistent with eosinophilic granulomatosis with polyangiitis have been reported with DUPIXENT in adult patients who participated in the asthma development program as well as in adult patients with co-morbid asthma in the CRSwNP development program. A causal association between DUPIXENT and these conditions has not been established.

5.4 Reduction of Corticosteroid Dosage
Do not discontinue systemic, topical, or inhaled corticosteroids abruptly upon initiation of therapy with DUPIXENT. Reductions in corticosteroid dose, if appropriate, should be gradual and performed under the direct supervision of a physician. Reductions in corticosteroid dose may be associated with systemic withdrawal symptoms and/or unmask conditions previously suppressed by systemic corticosteroid therapy.

5.5 Patients with Comorbid Asthma
Advise patients with CRSwNP who have co-morbid asthma not to adjust or stop their asthma treatments without consultation with their physicians.

5.6 Patients with Concurrent Asthma
Advise patients with CRSwNP who have concurrent asthma not to adjust or stop their asthma treatments without consultation with their physicians.

5.7 Parasitic (Helminth) Infections
Patients with known helminth infections were excluded from participation in clinical studies. It is unknown if DUPIXENT will influence the immune response against helminth infections. Treat patients with pre-existing helminth infections before initiating therapy with DUPIXENT. If patients become infected while receiving treatment with DUPIXENT and do not respond to anthelmintic treatment, discontinue treatment with DUPIXENT until the infection resolves.

6 ADVERSE REACTIONS
The following adverse reactions are discussed in greater detail elsewhere in the labeling:

• Hypersensitivity [see Warnings and Precautions (5.1)]
• Conjunctivitis and Keratitis [see Warnings and Precautions (5.2)]

6.1 Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Chronic Rhinosinusitis with Nasal Polyps
A total of 722 adult subjects with chronic rhinosinusitis with nasal polyposis (CRSwNP) were evaluated in 2 randomized, placebo-controlled, multicenter trials of 24 to 52 weeks duration (CSNP Trials 1 and 2). The safety pool consisted of data from the first 24 weeks of treatment from both studies. In the safety pool, the proportion of subjects who discontinued treatment due to adverse events was 5% of the placebo group and 2% of the DUPIXENT 300 mg Q2W group.

Table 4 summarizes the adverse reactions that occurred at a rate of at least 1% in subjects treated with DUPIXENT and at a higher rate than their respective comparator group in CSNP Trials 1 and 2.

Table 4: Adverse Reactions Occurring in ≥1% of the DUPIXENT Group in CRSwNP Trials 1 and 2 and Greater than Placebo (24 Week Safety Pool)

<table>
<thead>
<tr>
<th>Adverse Reaction</th>
<th>DUPIXENT 300 mg Q2W N=440 (n (%))</th>
<th>Placebo N=382 (n (%))</th>
</tr>
</thead>
<tbody>
<tr>
<td>Injection site reactions*</td>
<td>28 (6%)</td>
<td>12 (4%)</td>
</tr>
<tr>
<td>Conjunctivitis2</td>
<td>7 (2%)</td>
<td>2 (1%)</td>
</tr>
<tr>
<td>Arthralgia</td>
<td>14 (3%)</td>
<td>5 (2%)</td>
</tr>
<tr>
<td>Gastritis</td>
<td>7 (2%)</td>
<td>2 (1%)</td>
</tr>
<tr>
<td>Insomnia</td>
<td>6 (1%)</td>
<td>0 (0%)</td>
</tr>
<tr>
<td>Eosinophilia</td>
<td>5 (1%)</td>
<td>1 (&lt;1%)</td>
</tr>
<tr>
<td>Toothache</td>
<td>5 (1%)</td>
<td>1 (&lt;1%)</td>
</tr>
</tbody>
</table>

*Injection site reactions cluster includes injection site reaction, pain, bruising and swelling.
2 Conjunctivitis cluster includes conjunctivitis, allergic conjunctivitis, bacterial conjunctivitis, viral conjunctivitis, giant papillary conjunctivitis, eye irritation, and eye inflammation.

The safety profile of DUPIXENT through Week 52 was generally consistent with the safety profile observed at Week 24.

Specific Adverse Reactions

Conjunctivitis
In the 52-week CRSwNP study (CSNP Trial 2), the frequency of conjunctivitis was 3% in the DUPIXENT subjects and 1% in the placebo subjects; all of these subjects recovered [see Warnings and Precautions (5.2)].

Eosinophilia
DUPIXENT-treated subjects had a greater initial increase from baseline in blood eosinophil count compared to subjects treated with placebo. In subjects with CRSwNP, the mean and median increases in blood eosinophils from baseline to Week 16 were 150 and 50 cells/mcL, respectively.

Across all indications, the incidence of treatment-emergent eosinophilia (≥500 cells/mcL) was similar in DUPIXENT and placebo groups. Treatment-emergent eosinophilia (≥5,000 cells/mcL) was reported in <2% of DUPIXENT-treated patients and <0.5% in placebo-treated patients. Blood eosinophil counts declined to near baseline levels during study treatment [see Warnings and Precautions (5.3)].

Cardiovascular (CV)
In the 24-week placebo controlled trial in subjects with CRSwNP (CSNP Trial 1), CV thromboembolic events (CV deaths, non-fatal myocardial infarctions, and non-fatal strokes) were reported in 0 (0.7%) of the DUPIXENT group and 0 (0.0%) of the placebo group. In the 1-year placebo controlled trial in subjects with CRSwNP (CSNP Trial 2), there were no cases of CV thromboembolic events (CV deaths, non-fatality myocardial infarctions, and non-fatal strokes) reported in any treatment arm.

6.2 Immunogenicity
As with all therapeutic proteins, there is a potential for immunogenicity. The detection of antibody formation is highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of antibody (including neutralizing antibody) positivity in an assay may be influenced by several factors, including assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease.

For these reasons, comparison of the incidence of antibodies to dupilumab in the studies described below with the incidence of antibodies in other studies or to other products may be misleading.

Approximately 5% of subjects with atopic dermatitis, asthma, or CRSwNP who received DUPIXENT 300 mg Q2W for 52 weeks developed antibodies to dupilumab; ~2% exhibited persistent ADA responses, and ~2% had neutralizing antibodies.

Approximately 4% of subjects in the placebo groups in the 52-week studies were positive for antibodies to DUPIXENT; approximately 2% exhibited persistent ADA responses, and approximately 1% had neutralizing antibodies.

The antibody titers detected in both DUPIXENT and placebo subjects were mostly low. In subjects who received DUPIXENT, development of high titer antibodies to dupilumab was associated with lower serum dupilumab concentrations [see Clinical Pharmacology (12.3) in the full Prescribing Information].

Two subjects who experienced high titer antibody responses developed serum sickness or serum sickness-like reactions during DUPIXENT therapy [see Warnings and Precautions (5.1)].
7 DRUG INTERACTIONS
7.1 Live Vaccines
Avoid use of live vaccines in patients treated with DUPIXENT.

7.2 Non-Live Vaccines
Immune responses to vaccination were assessed in a study in which subjects with atopic dermatitis were treated once weekly for 16 weeks with 300 mg of dupilumab (twice the recommended dosing frequency). After 12 weeks of DUPLEXENT administration, subjects were vaccinated with a Tdap vaccine (Adacel®) and a meningococcal polysaccharide vaccine (Menomune®). Antibody responses to tetanus toxoid and serogroup C meningococcal polysaccharide were assessed 4 weeks later. Antibody responses to both tetanus vaccine and meningococcal polysaccharide vaccine were similar in dupilumab-treated and placebo-treated subjects. Immune responses to the other active components of the Adacel and Menomune vaccines were not assessed.

8 USE IN SPECIFIC POPULATIONS
8.1 Pregnancy
Pregnancy Exposure Registry
There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to DUPLEXENT during pregnancy. Please contact 1-877-311-8972 or go to https://matthertobaby.org/ongoing-study/dupixent/ to enroll in or to obtain information about the registry.

Risk Summary
Available data from case reports and case series with DUPLEXENT use in pregnant women have not identified a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. Human IgG antibodies are known to cross the placental barrier; therefore, DUPLEXENT may be transmitted from the mother to the developing fetus. In an enhanced pre- and post-natal developmental study, no adverse developmental effects were observed in offspring born to pregnant monkeys after subcutaneous administration of a homologous antibody against interleukin-4 receptor alpha (IL-4Rα) during organogenesis through parturition at doses up to 10-times the maximum recommended human dose (MRHD) (see Data). The estimated background risk of major birth defects and miscarriage for the indicated populations are unknown. All pregnancies have a background risk of birth defect, loss or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.

Data
Animal Data
In an enhanced pre- and post-natal development toxicity study, pregnant cynomolgus monkeys were administered weekly subcutaneous doses of homologous antibody against IL-4Rα up to 10-times the MRHD (on a mg/kg basis of 100 mg/kg/week) from the beginning of organogenesis to parturition. No treatment-related adverse effects on embryofetal toxicity or malformations, or on morphological, functional, or immunological development were observed in the infants from birth through 6 months of age.

8.2 Lactation
Risk Summary
There are no data on the presence of dupilumab in human milk. The effects on the breastfed infant, or on the effects on milk production. Maternal IgG is known to be present in human milk. The effects of local gastrointestinal and limited systemic exposure to dupilumab on the breastfed infant are unknown. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for DUPLEXENT and any potential adverse effects on the breastfed child from DUPLEXENT or from the underlying maternal condition.

8.4 Pediatric Use
CRSwNP
CRSwNP does not normally occur in children. Safety and efficacy in pediatric patients (<18 years of age) with CRSwNP have not been established.

8.5 Geriatric Use
Of the 440 subjects with CRSwNP exposed to DUPLEXENT, a total of 79 subjects were 65 years or older. Efficacy and safety in this age group were similar to the overall study population.

10 OVERDOSE
There is no specific treatment for DUPLEXENT overdose. In the event of overdose, monitor the patient for any signs or symptoms of adverse reactions and institute appropriate symptomatic treatment immediately.

17 PATIENT COUNSELING INFORMATION
Advise the patients and/or caregivers to read the FDA-approved patient labeling (Patient Information and Instructions for Use).
adverse reaction rates observed in the clinical trials of a drug cannot be
5.1 Hyperse

WARNINGS AND PRECAUTIONS
5.2 Conjunctivitis and Keratitis
(6.1, 6.2). In subjects with CRSwNP, the frequency of conjunctivitis was 2% in the
DUPIXENT group compared to 1% in the placebo group in the 24-week

polyposis (CRSwNP).

DUPIXENT is contraindicated in patients who have known hypersensitivity
to dupilumab or any of its excipients
Hypersensitivity reactions, including generalized urticaria, rash, erythema
reported in less than 1% of subjects who received DUPIXENT in clinical

development program. A causal association between DUPIXENT and these
eosinophilic pneumonia were reported in adult patients who participated
risks associated with systemic corticosteroid therapy. These events may be associated with the reduction

corticosteroid therapy. These events may be associated with the reduction

corticosteroid therapy. These events may be associated with the reduction

corticosteroid therapy. These events may be associated with the reduction

corticosteroid therapy. These events may be associated with the reduction

corticosteroid therapy. These events may be associated with the reduction

corticosteroid therapy. These events may be associated with the reduction

corticosteroid therapy. These events may be associated with the reduction

corticosteroid therapy. These events may be associated with the reduction

corticosteroid therapy. These events may be associated with the reduction

corticosteroid therapy. These events may be associated with the reduction

corticosteroid therapy. These events may be associated with the reduction

corticosteroid therapy. These events may be associated with the reduction

eosinophils from baseline to Week 16 were 150 and 50 cells/mcL,

In subjects with CRSwNP who have co-morbid asthma not to adjust or

Advise patients with CRSwNP who have co-morbid asthma not to adjust or

Patients being treated for asthma may present with serious systemic

Do not discontinue systemic, topical, or inhaled corticosteroid

Patients with known helminth infections were excluded from participation

Trial 1), CV thromboembolic events (CV deaths, non-fatal myocardial

These included serum sickness reaction, serum sickness-like

neutralizing antibodies.

were positive for antibodies to DUPIXENT; approximately 2% exhibited
persistent ADA responses, and approximately 1% had neutralizing

10-times the maximum recommended human dose (MRHD)

administration of a homologous antibody against interleukin-4-receptor

8.2 Lactation

on the breastfed infant, or the effects o

Eosinophilia 5 (1%) 1 (<1%)

Insomnia 6 (1%) 0 (<1%)

Table 4 summarizes the adverse reactions that occurred at a rate of at least
N=282

n (%)

safety = 7" X 10"
Q: What do you think is the most important issue that our Academy is currently facing? What are the strengths of the Academy that will lead us forward in our specialty and how will you capitalize on those strengths?

Richard M. Rosenfeld, MD, MPH, MBA

The most important issue facing our Academy can be summed up in one word: relevance. There is intense competition among specialty, subspecialty, and other nonprofit associations for relevance and member dues, which can no longer be taken for granted as an automatic renewal. Our Academy’s success rests with helping members succeed. Sustaining relevance means giving members the tools to be efficient, overcome challenges, and find joy in their work.

We can sustain relevance through value, diversity, and wellness. Value means a spectacular return on dues and volunteerism, with access to unique opportunities for personal and professional growth. Diversity and inclusivity are more essential than ever and can build upon existing committee efforts to address health disparities, improve workforce diversity, and promote equity and pipeline programs. Wellness initiatives, which at present focus largely on reducing stress and burnout, can be enhanced with lifestyle medicine, a new specialty that advocates for healthy eating, regular physical activity, restorative sleep, positive social connection, and avoiding risky substances.

The strengths of our Academy that will lead us forward are our diverse members, our incredible staff, and the synergy that flows from specialty unity. The strengths of our Academy that will lead us forward are our diverse members, our incredible staff, and the synergy that flows from specialty unity. Now celebrating its 125th anniversary, the Academy is more unified than ever. As Past Chair of the ENT Political Action Committee (PAC), I coined the byline “10,000 ENTs, 1 PAC, 1 Voice” to highlight the power of unity for political advocacy. Similarly, our unified voice in quality, education, research, communication, practice management, and international affairs transcends the efforts of smaller societies and empowers our members.

My qualifications to enhance relevance and unity stem from over three decades of Academy engagement, uniquely recognized with five Distinguished Service Awards. During this time, I attended every Annual Meeting and Leadership Forum, served on the Board of Directors for 10 years, and have generously supported the Hal Foster Endowment, Millennium Society, ENT PAC Leadership Club, Women in Otolaryngology (WIO) Endowment, Diversity Endowment, and many other causes.

I have seen firsthand the power of specialty unity in my roles as Journal Editor, Senior Advisor for Quality and Guidelines, and Chair of the Research Committee (now CORE), Guidelines Task Force (GTF), Science and Education Council (SEC), Cochrane Scholars Program, and the Subspecialty Advisory Council (SSAC). My degrees in public health and business administration, plus recent board certification in lifestyle medicine, set the stage for ongoing collaboration, innovation, and accomplishment.

Through member relevance and specialty unity we can achieve the unachievable and will continue to grow and shine as a specialty. I know what a gem our Academy is and how fulfilling participation can be; I want all members to benefit as much as I have.
The most important issue facing the Academy is maintaining relevance to otolaryngologists in a time of increasing subspecialization. Otolaryngology has grown in knowledge that benefits our patients in the ability to diagnose and treat many conditions with superior outcomes than previously imagined. The increase in specialization, however, has resulted in fragmentation within our specialty. Our specialty societies successfully promote scholarly activities and provide a home for their members. Often individuals have to choose between submitting presentations to their society or the Academy for purposes of career development.

We must make sure the Academy must maintain relevance. A definition of “relevance” is to maintain the ability to supply material that satisfies the needs of the user much like an information retrieval system. There are few of us who go a day without the use of Google, and much like that resource, the Academy needs to supply information to our members and be the go-to source for necessary materials. The pandemic was an example where the Academy served as a conduit for critical information, government policies, and advice on providing care while protecting ourselves, our patients, and our families.

Aristotle observed, “The whole is greater than the sum of its parts.” That is true for our specialty and for the Academy, but we need to remain vigilant and continue to prove our value to all practicing otolaryngologists if we are to thrive going forward.

Otolaryngology has been exceptional in its ability to recruit the most talented medical students for residency. Because of this, we enjoy the opportunity to train exceptional residents who become leaders in the field of medicine, not just in otolaryngology. I am always amazed at the individuals in our field who go on to become deans of medical schools, CEOs of their health systems, and medical directors or chiefs of surgical service lines. We all have watched as the “best of the best of the best” from our specialty have grown and ascended in their careers to leadership positions at national levels.

This talent is what sustains the Academy and allows it to flourish. The membership is involved, articulate, and motivated. Academy members gain value from those who lead the way and are routinely ahead of the curve. We are learners, and the strengths of the Academy are its members who continue to give of their time, knowledge, and passion for each other.
What do you see as the essential task of the Directors and in what ways are you well suited to that role? What do you think is the most important issue that our Academy is currently facing?

Alexander G. Chiu, MD

The Academy serves to represent the interests of all otolaryngologists, affiliated providers, and stakeholders. We are from different parts of the country, practice settings, and stages in our careers. But we share something very important and that is doing our absolute best to care for our patients. Whether that is through direct patient care, research, and/or education, the Academy is a vital engine to coordinate, innovate, and represent our shared mission in an inclusive and equitable environment.

I’ve been a member for 25 years and have a somewhat unique perspective in having practiced in three very different parts of the country. I spent the first part of my career in Philadelphia, Pennsylvania, then moved to Tucson, Arizona, and now reside in Kansas City, Missouri. I’ve been fortunate to hold many leadership roles during that time period, including chairing the Departments of Otolaryngology at the University of Kansas and University of Arizona and serving one year as a surgery chair. I am the current editor of ENT Today and have built working relationships with colleagues all across the country in private practice and academics and in both urban and rural settings.

Like all medical specialties, the Academy is in a time of change and needs to be mobile in adapting to the disruptions in the marketplace and the evolution to a more diverse environment where healthcare inequities need to be addressed. As industry support continues to decrease, we will need to find new and creative ways to engage our membership and support the education and research programs that are so critical in fulfilling our mission to provide the absolute best care to our patients. These issues are central to what I do in my daily work life and I am eager to help in any way possible.

Thank you for your support!

Sanjay R. Parikh, MD

Essential to the success of the BOD is to carefully listen to ALL constituents and to steer the BOD toward members’ greatest needs and concerns. I believe in responsive and representative leadership. In our AAO-HNS community, a successful Director listens and acts appropriately to all concerns from our membership.

I have been fortunate to serve in Academy leadership roles as Chair of the Board of Governors and Chair of the Young Physicians Section. During these terms, I participated in two AAO-HNS strategic planning retreats and served on the Academy’s Executive Committee and Nominating Committee. I have actively sought opinions from many grassroots groups including the BOG, WIO, YPS, SRF, IAB, and DIC. I feel particularly well suited for the position of At-Large Director as I have fostered successful collaboration between the diverse physicians and leadership of our membership.

Our Academy’s greatest issue is active support of our membership during this historic pandemic. We have already seen extraordinary leadership and community from our Academy and its members through responsive and adaptive attention to financial support for practices, development of new positions and paradigms for education, telehealth, research, and payment. But our work is not done.

As your At-Large Director, I will actively listen to your challenges and concerns and understand how the global pandemic has affected you. Our practices and loved ones have all been deeply shaken by this terrible year, and I would be sure to hear your perspective and thoughts on how our Academy may support you. The success of our Academy will hinge on understanding your needs. As we put these dark days behind us, we will work toward our best future together.
VOTE FOR ONE OF TWO

**candidate statements**

**at-large director: academic (four-year term)**

What do you see as the essential task of the Directors and in what ways are you well suited to that role? What do you think is the most important issue that our Academy is currently facing?

---

**Cherie-Ann O. Nathan, MD**

My journey from a young international research assistant at Johns Hopkins University to the department chair has given me a unique perspective on practice, research, and education in a collaborative setting. The crisis has brought the world closer through virtual meetings, and we have a great opportunity to be the leader for the world in all these areas, including mentorship.

We need visionary, hardworking, reputed leaders, listeners, and effective communicators who can continue to help the Academy be the powerhouse that unifies and leads the diverse world ENT community. As one of the few minority female chairs leading a highly productive academic department that works closely with private and public hospitals in rural and urban areas in Louisiana, I believe I am uniquely equipped to help enact.

If given the opportunity, I will work hard on strengthening the bonds between academics and private practice while broadening our horizons in terms of gender empowerment and diversity, and incorporating the latest technologies with greater emphasis on our mission, which is always putting our patients and their wellness first.

Adapting and leading in the post-pandemic world is our highest priority at the moment. We have a unique opportunity to provide access to every corner of the world in terms of outstanding patient care, educational opportunities, and mentorship programs. I envision the Academy embracing the latest technologies in terms of apps, servers, robotics, and AI to become the global hub collaborating with all the societies and organizations.

---

**Robert T. Sataloff, MD, DMA**

The essential task of an At-Large Director is to identify and help fulfill the needs of our specialty, while expanding recognition of the Academy’s relevance and engaging otolaryngologists (academic and private) in our national organization. I hope to help by providing perspectives gleaned from a 40-year career in academic otolaryngology integrated with a self-employed clinical practice model.

As professor and chair and senior associate dean at Drexel University, I am employed for academic and leadership activities, but my clinical practice is independent. While being active academically (more than 1,000 publications, including 69 books, and journal editor), I have advocated for private practice interests. I also serve as the Academy’s representative to the AMA for impairment (AMA Guides), spent more than 20 years on the Voice Committee (six as Chair), served as a member and Chair of the Geriatric Committee, have served on the Board of Governors for 16 years, have taught Academy courses, and presented papers and seminars for four decades. I have served in numerous other leadership capacities for the Academy and the specialty including president of the American Laryngological Association, president of the American Society of Geriatric Otolaryngology, president of the Pennsylvania Academy of Otolaryngology - Head and Neck Surgery (PAO-HNS), and others. I remain active on the PAO-HNS Council and am involved actively in legislative and political advocacy on behalf of otolaryngologists. In addition, I proposed and helped initiate the AAO-HNS/F annual leadership meeting of state society presidents and executive directors.

I support all of the objectives in the Academy’s strategic plan, but the most important is “quality.” Developing and promulgating excellence is the foundation upon which all of our initiatives must be built, and doing so in the current environment is the most important issue that the Academy is facing.

I would be honored to help.
What do you see as the essential task of the Directors and in what ways are you well suited to that role?

What do you think is the most important issue that our Academy is currently facing?

Jeffery J. Kuhn, MD, CAPT, MC, USN (Ret.)

The essential tasks of the Board of Directors are to assess the overall direction and strategic plan of the Academy, support the mission and vision of the Academy, and to establish new initiatives that forward the voice of the membership. The Board of Directors should identify and understand the most important issues facing the Academy. It is critical that the Directors have leadership experience and have demonstrated integrity, ingenuity, and commitment in those leadership positions.

I have served in a number of leadership positions in various venues including military academic and nonacademic centers, a university academic center, and now in private practice for the past six years. I have served on six Academy Foundation Committees and recently completed a three-year term as a member of the Nominating Committee, AAO-HNS/F.

As a former collegiate athlete, physical and mental wellness were paramount in determining performance outcome. Performance outcomes in our professional lives are similarly influenced by these factors. As much as we attempt to maintain personal wellness in our professional career while establishing a health-life balance, there is great potential for physical, emotional, and mental exhaustion. Physician burnout has become an important issue throughout the medical specialties and should be a focus of attention within our Academy. Frequent changes in clinical practice involving EMR system platforms, telehealth policies, workload expectations, and administrative burdens, in addition to loss of independence and authority, heightened patient expectations, and a culture that emphasizes perfection are several factors that contribute to the erosion of physician well-being. I would expand the current Wellness Team initiative in the form of a task force that would interface with other Foundation Committees including Media and Public Relations, Telehealth, Practice Management Education, and Diversity and Inclusion in order to identify factors unique to the otolaryngologist and to propose evidence-based solutions.

Angela M. Powell, MD

Being an active-duty U.S. Navy ENT for almost 14 years, juxtaposed with my current rural civilian practice, have together reinforced the true value and necessity of member involvement and service to the Academy. The tenet that collectively we can achieve inordinately more in advancing excellence in the delivery of care to our patients than any one of us could do individually has been aptly demonstrated in the Academy’s response to the COVID-19 pandemic. Allow me to represent private practitioners and be your voice on the BOD as we work to reduce healthcare disparities in underserved communities, to continue legislative advocacy, to educate and promote lifelong learning, to increase diversity within the specialty, to promote wellness, and to engage and mentor young leaders. I have been involved in each of these areas through my roles in the SRF, on BOG Committees, chairing the Barnes Society, and as the Immediate Past Chair of the WIO. Thank you for your vote of support.

The importance of wellness to the Academy’s primary initiatives cannot be overstated. Consider overcoming the financial impact to our practices by the pandemic; office closures; the death of colleagues, loved ones, and patients; exhaustion; and burnout while the guidepost to normalcy remains elusive and the stage is set. EHR inefficiencies, navigating telehealth services, the new E/M visit guidance from CMS and how these changes will affect reimbursements (anticipating a net positive but implementation will serve as the true measure), and the uncertainty of what ENT practice will become in the post-vaccine era further heighten stress and angst for many. Wellness is inextricably linked to the love that we all have for this amazing field and, therefore, must remain in the forefront for the Academy’s efforts to be meaningful and impactful as we educate, lobby, mentor, innovate, and lead.
How will you select candidates for Academy leadership that best represent our diverse membership? What experience do you have that will aid in selecting leaders that will advance the mission of the Academy?

**SEAT ONE**

**Ronda E. Alexander, MD**

Our Academy needs a balance of experienced and emerging voices to serve our membership. The lived experiences and practical expertise of those from historically marginalized perspectives can advance our mission when positioned to impact our actions and policies. Many of them are already leading other academic and identity-affiliation organizations, while others are the quiet engines behind them. These are the willing workers I want to call up into Academy service, better equipping us for a future in which we will face unknown challenges in the realms of public health, patient care, and advocacy.

As a former residency program director, I have seen the benefits of selecting strong introverted candidates, then cultivating an environment that doesn’t disadvantage them, relative to extroverts. Many of the “best of the best” have been the quiet ones, and this reinforces the importance of breaking “type” when we look for excellence. My work with my state medical society has complemented this by highlighting the importance of moving from mentoring to sponsoring people whose spark I can see, even if they haven’t yet. Having been a beneficiary of sponsorship, I’m looking forward to encouraging others to put their potential to good use within the Academy.

**Samantha Anne, MD, MS**

“Here’s to the crazy ones, the misfits, the rebels, the troublemakers, the round pegs in the square hole, the ones who see things differently …” This narrative from a popular tech company advertisement follows with a description of how these are the people who change things.

The importance of thinking innovatively became clear to me especially during the past year. I believe that the way to capture these resourceful intellectuals is to draw from our incredibly heterogeneous membership to find leaders with integrity who have proven to be inventive trailblazers.

I have served on various leadership roles in the American Academy of Otolaryngology—Head and Neck Surgery, including on the Board of Directors (as Young Physician Section Chair) and on the Board of Governors (as Secretary and current Vice Chair of the Governance and Society Engagement Committee). In addition, I have been the Chair of the Women in Otolaryngology Section’s Nominating Committee. This service afforded me the chance to observe the leaders, and the qualities that elevate them as successful advocates for our profession.

This experience along with my motivation to identify talented and innovative leaders, will guide me if I am given the incredible honor to serve on the Nominating Committee.

**SEAT TWO**

**Ken Kazahaya, MD, MBA**

It is wonderful that we have such diversity in the membership of the Academy. With the global nature of our specialty, our organization encompasses members from various practice settings, organizational structures, geographic locations, and demographics. There is also great diversity in the individuals themselves, inclusive of unique origins and experiences, ages, ethnicity, and orientation. Our Academy’s strength is in our membership’s diversity of thought, experiences, and culture. It is important to keep an open mind and be inclusive in selecting individuals who have the necessary talents, skills, and experiences to best lead our Academy while considering the merits and accomplishments of each individual.

I had the honor of being elected to the Nominating Committee for the American Society of Pediatric Otolaryngology. As part of the Nominating Committee, I participated in discussions regarding the various considerations prioritizing qualities and attributes that are important and optimal for the positions we were seeking to select nominees. It was essential to be able to succinctly and effectively summarize the candidates under consideration and support their candidacy. I advocated considering individuals for their qualifications and what they would contribute to the leadership of the organization.

**Brendan C. Stack, Jr., MD**

I will propose and advocate for Academy members for leadership opportunities who have great passion for our specialty and extending its impact to ALL of our patients and learners regardless of their background, identity, or circumstance. A record of demonstrated impact will be required for my nomination or support. I will seek consensus from among members of the nominating committee to ensure a quality selection with strong, broad support. I will take seriously that the selection of future candidate leaders as a crucial task to ensure that our organization represents our membership and flourishes into the future.

I have learned to recognize leaders from over 30 years of observation of both good and bad examples of leadership. Those experiences have both educated me, inspired me to seek greater understanding of GREAT leadership, and driven me to identify those characteristics crucial for inspiring successful leaders. My value of a strong and effective leader is profound and inspires me on my personal leadership journey. Moreover, having served in various leadership capacities within the AAO-HNS/F, the American Thyroid Association, and the American Head & Neck Society – Endocrine Surgery Section, I have learned the importance of leading by example, building and maintaining relationships, and making and keeping commitments.
Q: How will you select candidates for Academy leadership that best represent our diverse membership? What experience do you have that will aid in selecting leaders that will advance the mission of the Academy?

SEAT ONE

Andrew M. Coughlin, MD

While the Academy has made strides in creating diversity within our membership, we have seen some but limited success in obtaining diversity at the leadership level. As a member of the Nominating Committee, I will work hard to not only focus on diverse backgrounds, practice settings, and experience levels, but I will also aim to promote those who have put forth significant effort in elevating those around them. Leadership is best exemplified by supporting and promoting your peers. Teamwork and an “others first” mentality will be at the forefront of my decision making.

As Chair of the Engagement Task Force for the Young Physicians Section, past governor of the Nebraska Academy of Otolaryngology, and as a member of the Nominating Committee for the Metro Omaha Medical Society, I have a lot of experience in encouraging and mentoring strong candidates for positions of leadership. It is my hope that I will continue this work for the greater good of the Academy to make our entire community more impactful and representative of all otolaryngologists and the patients we serve. I very much appreciate this opportunity and promise to represent you all to the best of my ability.

SEAT TWO

Darius Kohan, MD

During my 30-year career in private practice and academics, I had the privilege of collaborating with colleagues from all aspects of otolaryngology throughout the United States. Participating in numerous BOG and AAO-HNS Committees, I got to know and appreciate the outstanding dedication and leadership quality demonstrated by our members. In private practice, especially during the pandemic, I am familiar with all the challenges facing us and the opportunities available for improving the welfare of our patients and the well-being of the otolaryngologists attempting to optimize patient care. Participating in regional and national efforts to promote Academy goals, educate the next generation of otolaryngologists, and improve patient care, while collaborating with our peers in all fields of medicine, allowed me to personally become familiar with the large pool of talent available to the Academy. Their work ethic and dedication to benefit the welfare of our patients and achieving Academy goals was amply demonstrated. I intend to nominate the most deserving otolaryngologists to leadership positions based upon merit and ability to represent our evermore diverse membership. Leadership must reflect the needs of both private practitioners and academicians, the geography and demographics of our country, and the vision of the Academy for a brighter future.

Russell B. Smith, MD

We are fortunate in otolaryngology-head and neck surgery to have a very diverse and engaged membership. We currently have a large number of these talented surgeons involved at many levels throughout our society. I would plan to recommend candidates for Academy leadership by recognizing these currently engaged members, many of whom I have worked with on a variety of education and program committees in my 20 years of involvement with AAO-HNS. I would also reach out to these members for recommendations of up-and-coming younger members who will be able to positively contribute to the ongoing success of our Academy.

Over my years of experience with residency and fellowship training programs, hospital governance, and medical practice development, I have been involved with selecting individuals to be part of a team to move forward the mission of an institution. Through these experiences, I feel that I understand that leadership requires a diverse team of individuals with uniquely different skills to be successful. I plan to use these experiences to recommend candidates with a wide variety of skills to fulfill the needs of the different leadership positions within our Academy.

Angela K. Sturm, MD

As a member of the Nominating Committee, I would be excited to have a hand in choosing leaders who represent our membership professionally and personally. It is important to bring voices to the table with different perspectives. In the environment of reimbursement challenges, increasing overhead, changing protocols, increased expenses for the pandemic, and complex patients, the private practice physician’s representation is critical. As the owner of my own private practice, I understand those challenges. In addition, I am sensitive to how those physicians’ time spent away from their practice must be optimized to retain engagement. We also need to keep in mind the demographics of our membership currently and where we anticipate growing. As our membership is more diverse, we need leadership that reflects that and understands unique challenges that they may have. I have spent a large portion of my career working for diversity and inclusion, from giving lectures on the healthcare needs of gender minorities to furthering discussions about how to improve healthcare delivery for racial minorities. I appreciate the wisdom from those who know where we have been and gain inspiration from those who are our future.
Q: What is your particular experience or interest that would make you an effective member of the Audit Committee of the Academy?

Art A. Ambrosio, MD, MBA

A guiding principle in the U.S. Navy is “Ship, Shipmate, Self.” I have been an active member and advocate on behalf of AAO-HNS/F, prioritizing it in my career as my “Ship” since early in my surgical residency, serving on the BOG Legislative Affairs and Governance & Society Engagement Committees—allowing me to understand and protect the strategic mission of the Academy on a local, state, and federal level.

Completing formal business training at UNC Kenan-Flagler Business School in addition to my full-time surgical practice prepared me for involvement in Navy enterprise-wide leadership roles. A major venture has been in founding the first-ever virtual Naval Medical Center (VNMC) in San Diego, California, which supports tri-service military medical treatment facilities as well as deployed ground and fleet forces throughout the entire Pacific Rim. As deputy director of the VNMC, I have provided thorough operational oversight of security, policy, and budget allocation for the programs we have built within this rapidly scaling venture during the COVID-19 pandemic.

I am ultimately looking to leverage my strengths, energy, and passion to serve the Audit Committee—ensuring transparency and attention to detail to ensure that our precious resources are properly supporting the mission of the Academy and its members.

Steven B. Levine, MD

The Audit Committee is the entity that maintains transparency of the operational and financial condition of the Academy. It is a critical function.

I have been a member of the Academy since the mid-1980s and have been faculty for Academy instruction courses and served on the Practice Management Committee, Professional Liability Committee, Certificate Program for Otolaryngology Personnel Committee, Ad Hoc Committee on an Otolaryngology Risk Retention Group, and Physician Resources Committee. I have been active on the BOG, including election as Secretary as well as Vice Chair of the Socioeconomic & Grassroots Committee.

My medical career has all been in private practice, including group practice with multiple offices and solo practice of late. My interests outside of my medical practice, however, have afforded me a broader experience and scope of understanding of the operations of various businesses. I have started several companies that categorize me as an entrepreneur and am a cofounder of the Society of Physician Entrepreneurs. I have been a director of a publicly held bank and served on its loan committee, thus affording me unique experience interacting with both internal and external auditors. These interests and experiences support my candidacy for this position.
Tracheostomy Care

Lacey K. Adkins, MD. Laryngology and Bronchoesophagology Education Committee member

Tracheostomies are one of the most-performed surgical procedures, and the incidence has continued to rise. Tracheostomy care is a broad topic that includes patient and caregiver education, postoperative care, and decannulation protocols. It is a complicated process that requires the otolaryngologist to work as part of a team on behalf of the patient. It has recently been identified as a practice management gap.

Tracheostomy Care begins in the immediate postoperative period. Tracheostomy ties should be used unless there is a surgical contraindication such as free flap reconstruction. Velcro or twill ties may be used with no consistent difference in skin-related complications or decannulation rate.1 Stay sutures may decrease the incidence of accidental decannulation in fresh tracts.2,3 They should be tied with air knots and removed within seven days to avoid excess pressure and resulting pressure ulcer formation.

Pressure ulcers occur in 10%-30% of tracheostomies.4,5 Having a set tracheostomy care protocol, especially one that involves a multidisciplinary team to identify and provide wound care, helps reduce their incidence. Moist dressings applied peristomally result in a lower incidence of pressure ulcers, shorter wound closing times, and less frequent dressing changes.6

In the early postoperative period, secretions are more copious. Frequent suctioning and care with saline flushes as needed are key to avoiding mucous plugging.7 Humidification should be used to help mobilize secretions. Prior to cuff deflation and tracheostomy change, the tracheostomy and stoma should always be suctioned.8

A multidisciplinary tracheostomy team not only reduces wound complications, but improves time to decannulation, decreases the length of stay, reduces adverse events, and increases speaking valve usage.9 A consistent approach with adequate staff training and early coordination of care can help patient and caregiver education, as well as the discharge process.10 Patients and caregivers must learn and demonstrate essential tasks before being discharged, including hands-on tracheostomy care training with simulation of emergency situations.4

Early involvement of a speech-language pathologist leads to earlier phonation and transition to an oral diet. Some patients can tolerate early cuff deflation and in-line speaking valve placement while still receiving mechanical ventilation safely.11,12 Once off mechanical ventilation, the cuff should be deflated or the tracheostomy changed to an uncuffed tube to decrease further tracheal pressure injury.9 This also allows for phonation with a one-way speaking valve. If the patient has an appropriately sized tube and is unable to tolerate the valve, the upper airway needs to be examined to evaluate for any abnormalities. If they can tolerate a valve but the voice is soft, a fenestrated tracheostomy tube may allow more air to reach the glottis. However, they require close monitoring as patients can develop granulation tissue at the site of fenestration that needs to be managed before leading to airway obstruction.13 One could argue that the choice of a fenestrated tracheostomy would be best made with the consultation of an otolaryngologist.

For patients who require long-term tracheostomy dependence, biofilms and the tracheal environment eventually lead to hardware degradation. Frequent tracheostomy change may result in less granulation tissue formation. Tracheostomy manufacturers have recommended changing intervals with their products, which is usually one month. In the literature, there is extensive variability on recommended intervals ranging anywhere from two weeks to every three months and especially whenever the tube begins to change color or has visible degradation or cracks.14,15

For weaning and decannulation, having a set protocol leads to a higher rate of decannulation during the hospital stay and a decreased time to decannulation.9,16 Before decannulation, the patient should no longer require mechanical ventilation and have no further procedures planned, an intact cough reflex and an appropriate mentation and laryngopharyngeal function to protect themselves from aspiration. A capping trial should then be started with an uncuffed, appropriately small tube in place and may last anywhere from 24 to 72 hours depending on surgeon preference. The upper airway should be examined prior to decannulation as well by at least laryngoscopy and tracheoscopy. In patients who tolerate capping trials for 24 hours, up
to 20% have lesions on endoscopy that are a contraindication to decannulation.17

After decannulation, follow-up is needed to assess for tracheal fistula closure and to monitor for any stenosis symptoms. Roughly 1%-2% of patients will report symptoms of benign tracheal stenosis after decannulation, whether from scarring, tracheomalacia, or A-frame deformity, usually after a delay of two to three months.18

In conclusion, tracheostomy is an increasingly common procedure that has extensive care associated with it. The biggest step to take toward improving outcomes is to establish a multidisciplinary tracheostomy team that follows the patient in the hospital as well as a plan for follow-up post discharge. With non-otolaryngologists performing tracheostomies, the otolaryngologist has an important role to play in follow-up planning. This helps to facilitate appropriate wound care, progression toward decannulation, and patient/caregiver education.

References
D o humans cause patient harm, or do we prevent it? Efforts to improve patient safety have—appropriately—received a lot of attention and resources over the past two decades, with some progress but many remaining challenges.¹–³

Like the note on the stop sign in the photograph to the right, sometimes looking at our activities from a different perspective can change our understanding, and a fresh perspective might increase our appreciation for the work that we do every day to optimize patient safety.

Safety-I
The traditional perspective on patient safety, Safety-I, is generally based on the belief that we should investigate healthcare events in which patients were harmed, figure out what failed, and build in barriers to prevent recurrence. When there is an unwanted outcome, we expect to find breaches in protocols or other defenses that caused—or at least allowed—the problem to occur. Humans are often seen as a liability or hazard, and we expect optimal outcomes if processes are standardized and healthcare workers behave as trained.⁴–⁵ However, patients may not do well despite our most learned and skilled efforts, and patients sometimes do well for reasons that we don’t completely understand. There is a complementary perspective, Safety-II, which seeks to learn from what went right, acknowledges complexity, and values adaptation.

Safety-II
The majority of patient care interactions go well. This is not to say that we shouldn’t always look to improve and recognize our shortcomings, but there can also be value in understanding and augmenting successful processes. The Safety-II perspective advocates for deliberate investigation to understand what decisions, actions, or adaptations contributed to successful patient outcomes.⁴ Understanding whether the desired outcome resulted from our ability and effort, rather than from luck,⁶ can help improve care going forward.

What can we learn from studying what went well? Examples from other fields are never quite sufficient, but still may offer perspective. K. Anders Ericsson, famous for describing the importance of deliberate practice to achieve expert performance, posits that improvement is based not just on repetition, but also requires explicit exposure to the best method.⁷ Shmuel Ellis and Inbar Davidi found the performance of soldiers who were debriefed on their successes as well as their failures during successive navigation exercises showed greater improvement than soldiers who reviewed their failed events only.⁸ This makes sense in healthcare also, such as when developing surgical skills. Learners (all of us!) need to understand what we have done right as well as what we may need to improve. This understanding of what went well goes beyond the kudos received for an extraordinary job well done and involves an effort to learn why.

Safety-II also posits that adaptation—performance adjustment—is both necessary and ubiquitous.⁴ We provide healthcare despite work conditions that are both dynamic and underspecified. The impact of factors that can impair performance may be momentary but recurrent, including competing demands, production pressure, and resource limitations. Successful patient care results from innumerable small adjustments, often unrecognized, or, in rigid systems, accomplished surreptitiously. In this perspective, humans are not liabilities to be managed, but are important resources who contribute to system flexibility and resilience.⁴ Although not always explicitly recognized, many organizations have responded to the COVID-19 pandemic with behaviors that exemplify Safety-II
and resilience engineering principles. Providers have self-organized groups that convene by video conference call and share information about process improvements and lessons learned to proactively minimize risk and improve safety for both patients and providers. Organizations have implemented simulations to develop and revise patient care protocols, refine methods to correctly don and doff personal protective equipment, and enhance communication between providers despite physical barriers necessitated by isolation practices. 8

Safety-II Is a Frame Shift
Maintaining a Safety-II perspective, which reinforces correct decisions and actions, sometimes takes conscious effort. For example, when debriefing participants in simulations, it is easy to criticize whereas seeking to surface and understand tacit knowledge and constructive actions often requires intentional reorientation. The Safety-II approach is also applicable to ordinary processes. It can be difficult to expend energy understanding everyday activities in addition to exceptional successes or failures; however attention to commonplace processes, because of their frequency, may provide the greatest benefit.

Finally, consistently modeling respect and appreciation for colleagues’ actions and perspectives provides an affective lesson; and learning from success can help us appreciate the value of system capacities and resources that might otherwise be lost in efforts to constrain costs.

Safety-I and Safety-II Can Co-Exist
Can these different approaches be reconciled? Healthcare delivery is a complex adaptive system; interactions and conditions constantly evolve and are incompletely knowable. The Safety-I approach of fixing each part of a system in a mechanistic fashion does not always guarantee that the whole will work as desired, but there are circumstances in which standardized protocols are optimal. Conversely, there are inevitable gaps between idealized “work-as-imagined,” which often informs policy, and actual “work-as-done,” 4,9 which is the experience of providers at the “sharp end.” We can seek to improve by understanding and appreciating the knowledge, skills, behaviors, resources, and environments that contribute to success, and by recognizing the value of adaptive solutions. The Safety-II approach helps develop resilient capacities that support continued and safe healthcare delivery despite small or large perturbations. 10 Healthcare delivery involves unique high-hazard processes, and the complementary perspectives of Safety-I and Safety-II can both contribute to providing the safest patient care.

References
**ASPIRATION**

Aspiration is a medical term for accidentally inhaling your food or liquid through your vocal cords into your airway, instead of swallowing through your food pipe, or esophagus, and into your stomach. Once past the vocal folds, the food or drink enters your windpipe, or trachea, and can pass into your lungs. It happens sometimes to healthy people who have food “going down the wrong pipe” while swallowing. When this happens, a normal voice box, or larynx, and trachea sense the food or drink, which triggers a strong cough to clear the item from your windpipe and protect your lungs.

**WHAT ARE THE SYMPTOMS OF ASPIRATION?**

When swallowing becomes difficult, or the sensation of your throat or voice box becomes impaired, anything that passes through your mouth can get into your lungs, even saliva, which is full of bacteria. Symptoms of aspiration may include:

- Strong coughing
- Choking while eating
- Pneumonia
- Trouble swallowing
- Stress while eating
- Weight loss

Again, aspiration is of great concern because it increases your risk of developing pneumonia.

**WHAT CAUSES ASPIRATION?**

Aspiration can happen for many reasons and often should be looked at by an ENT (ear, nose, and throat) specialist, or otolaryngologist. If you have frequent coughing while eating or drinking, this is a sign you should see a doctor about swallowing problems. Given the possibility that aspiration might lead to pneumonia, finding it early is important. Sometimes when a stroke or other condition makes the vocal cords less sensitive, coughing may not be a signal that you are having difficulty swallowing, which can lead to silent aspiration.

**WHAT ARE THE TREATMENT OPTIONS?**

Doctors often ask other healthcare providers such as speech-language pathologists (SLP) to help test swallowing problems. They may use a small camera placed through the nose to examine how food passes by the voice box into the esophagus during a swallow. Testing may also include a special X-ray video, called a modified barium swallow. This allows the SLP and doctor to watch the food pass through the entire swallowing activity from lips to esophagus. These tests may show what is wrong in the swallowing process, and help them figure out how to help you eat and drink safely.

Sometimes, simple diet changes are all that is needed to prevent aspiration. Other cases may need swallowing therapy. During therapy, exercises for swallowing strengthen and coordinate the muscles used in swallowing. Some swallowing problems may need surgery. Unfortunately, in certain situations, swallowing is so difficult or unsafe that a person cannot take in any food or drink by mouth. Then, interventions like a stomach feeding tube can supply food and fluids. In these situations, your doctor(s) and clinical team will work to help you find treatment(s) to regain a safe, effective swallow.

If you have any questions or concerns about suspected aspiration for you or a loved one, please find a nearby ENT specialist for consultation.

**WHAT QUESTIONS SHOULD I ASK MY DOCTOR?**

1. What is the difference between choking and aspiration?
2. Do you know why I have difficulty swallowing?
3. What are the tests for my swallowing problem?
4. Did I get pneumonia from aspiration?
5. What is the treatment for aspiration?
6. What is the oral care regimen for people that aspirate?
7. Do I need a feeding tube?
8. What is swallowing therapy?
Positions are available at the Assistant or Associate Professor level in the Department of Otolaryngology-Head & Neck Surgery

**PEDIATRIC OTOLARYNGOLOGIST**
- Excellent opportunity at our Children’s Hospital of Georgia
- Rank commensurate with experience
- Excellent resources are available
- Fellowship training required

**OTOLOGIST/NEUROTOLOGIST**
- Rank commensurate with experience
- Excellent resources are available
- Fellowship training required

To apply and receive additional information, please contact:
Stil Kountakis, MD, PhD
Professor and Chairman
Department of Otolaryngology-Head & Neck Surgery
1120 Fifteenth Street, BP-4109
Augusta, Georgia 30912-4060
Or email skountakis@augusta.edu

---

**Do you have a position, course, or meeting you would like to promote?**

The Bulletin is the perfect vehicle to reach your audience. Contact Suzee Dittberner today at 913-344-1420 or sdittberner@ascendmedia.com.
Cooper University Health Care

The Division of Otolaryngology-Head & Neck Surgery at Cooper University Hospital (located in southern New Jersey just across the bridge from Center City Philadelphia) is seeking a General Otolaryngologist to join our busy academic/clinical practice. Candidates with strong interests and capability in Otology, Sleep surgery, and Laryngology are desired.

This is a unique and desirable opportunity to join our energetic, busy and collegial group of 5 attending physicians. You will be walking into a turnkey practice with a backlog of patients ready to fill your clinic schedule. In your new position you will also serve as an important faculty member for our ACGME accredited Otolaryngology residency training program that started in July 2019. You will be working with, teaching and training residents and will carry an appointment in the medical school commensurate with your professional experience. Clinical research opportunities exist and are strongly encouraged through the Department of Surgery and you will have ample support in these endeavors from the medical school and residents.

In addition to resident coverage our attendings also receive strong inpatient support from our Advanced Practice Providers (NPs / PAs) who do an excellent job of managing consults, admissions and in-patients on our service.

Compensation and benefits are extremely competitive and after the first year of practice you will be eligible to be compensated based on your clinical productivity which has been very rewarding for our current faculty. South Jersey, where our practice is located, and nearby Philadelphia as well as the surrounding suburbs, offer desirable housing, dining, school and recreational opportunities. In addition to the local attractions, we are located 1 hour from the New Jersey beaches, 1 hour from the Poconos Mountains, 2 hours from Manhattan, and 2.5-3 hours from Washington DC and Baltimore.

Our team enjoys a healthy work/personal life balance, and pride themselves on the scope and quality of practice provided at Cooper University Hospital. We are seeking a like minded individual to join our close knit and busy practice. Start date in July/August 2021.

Direct Contact Information:
Interested candidates should send their CV and cover letter to: Dr. Nadir Ahmad, Division Head, ahmad-nadir@cooperhealth.edu

Gerald L. Gilroy, D.O.
F.O.C.O.O., F.A.A.O.A

OTOLARYNGOLOGY & ALLERGY CLINIC

Opportunity to purchase a well-established, solo practice in Otolaryngology and Allergy in East Lansing, Michigan. Practice specialties include: Otolaryngology, Allergy and Audiology, including a partnership in hearing aid sales and service. Longevity of the practice has established a large referral base. Physician is Board Certified in Otolaryngology, Oto-Facial Plastic Surgery and Otolaryngic Allergy. Physician is willing to transition with the practice for one year, if desired. Coveted retro equipment offered for sale, as well as surgical instruments in excellent condition.

East Lansing is supported by Sparrow Regional Hospital and McLaren Regional Medical Center and the Lansing Surgery Center. University Corporate Research Park, a joint project with McLaren and MSU, includes a new 450 million dollar hospital to be completed in 2021. The Colleges of Human Medicine and Osteopathic Medicine offer teaching opportunities at Michigan State University.

East Lansing is the home of Michigan State University providing cultural and entertainment opportunities through its athletic programs (MSU Spartans), the Eli-Broad Art Museum and the Wharton Center for Performing Arts. Neighboring city of Lansing is the State Capital of Michigan. Michigan offers great year-round recreational opportunities including the Great Lakes, hunting, skiing and golf.

If interested, please contact: Jay at jay@geraldgilroy.com or 517.285.0621.

Employment Opportunity for a Hospital Employed Otolaryngologist in the heart of the Gorgeous Adirondack Mountains of Northern New York

Join our Facial Plastic Surgeon in a busy, well established outpatient center.

- Brand new State-of-the-Art OR with 2 minor surgery rooms.
- Dedicated OR time.
- Sinus navigation system.
- This practice is well supported by primary care Physicians as well as Specialists' referrals.
- Courtesy ER calls are valued, and there is no trauma call!
- Healthy mix of Adult/Pediatric population.
- Interest in otology is welcomed.

This position comes with a generous benefits package and competitive salary, centered in an employee friendly environment.

Qualified candidates who are Board Certified with an unrestricted license to practice medicine are invited to apply by contacting Joanne Johnson at jjjohnson@adirondackhealth.org.

Come live where others vacation!

- Flexible schedules
- Competitive salaries & benefits
- Unparalleled quality of life
- Family friendly community
- Excellent schools, both private and public
- Gated nearby Whiteface Mountain ski resort
- Home of the 1932 & 1980 Winter Olympics
- World Cup Bobsled and Ski Events
- Home of Paul Smith's College (ranked #2 for Most Innovative School)

Hike, fish, ski, golf, boat or simply relax and take in the beauty and serenity of the Adirondack Region.

www.adirondackhealth.org
The Department of Otolaryngology – Head & Neck Surgery at the University of Illinois at Chicago and the University of Illinois Hospital and Health Sciences System is seeking applicants specializing in Head and Neck Surgery:

### Assistant Professor in Otolaryngology

This is a full-time faculty position, with tenure-track to be determined commensurate with interest. We are seeking faculty with experience in expirative, reconstructive, and robotic surgery to join our dynamic and growing clinical academic practice as part of a team-centered approach to patient care. As part of the largest medical school in the US, those interested in pursuing clinical or translational research will find a supportive infrastructure and diverse patient population.

Duties and interest to include providing direct patient care, supervising residents and medical students, and pursuing clinical or translational research. Applicants must be Board certified or eligible, and fellowship trained. For fullest consideration, application must be received by March 15, 2021. Applications will be reviewed on a rolling basis. Interested applicants should send their curriculum vitae to:

Barry L. Wenig, MD, MPH, MBA FACS  
Mario D. Mansueto Professor and Head  
Department of Otolaryngology-Head & Neck Surgery (M/C 648)  
University of Illinois at Chicago  
1855 West Taylor Street, Room 2.42  
Chicago, IL 60612  
Phone: (312) 996-6582, Fax: (312) 996-1282  
Email: ENTHR@uic.edu  
www.otol.uic.edu

The University of Illinois at Chicago is a major clinical and research university offering the cultural, business and entertainment opportunities you can only find in a world-class city. For more information, please visit www.uic.edu or http://research.uic.edu

The University of Illinois at Chicago is an affirmative action, equal opportunity employer. All qualified applicants will receive consideration for employment without regard to race, color, religion, sex, national origin, protected veteran status or status as an individual with a disability.

The University of Illinois conducts background checks on all job candidates upon acceptance of contingent offer of employment. Background checks will be performed in compliance with the Fair Credit Reporting Act.

FOR MORE INFORMATION, PLEASE CONTACT:  
David Goldenberg, MD, FACS, Chair, Department of Otolaryngology – Head and Neck Surgery  
Department of Otolaryngology – Head & Neck Surgery Center by the American College of Surgeons Children’s Surgery Verification Program.

Penn State Health is fundamentally committed to the diversity of our faculty and staff. We believe diversity is unapologetically expressing itself through every person’s perspectives and lived experiences. We are an equal opportunity and affirmative action employer. All qualified applicants will receive consideration for employment without regard to age, color, disability, gender identity or expression, marital status, national origin, genetics, race, religion, sex (including pregnancy), sexual orientation, veteran status, and family medical or genetic information.

Penn State Health is an equal opportunity and affirmative action employer. All qualified applicants will receive consideration for employment without regard to age, color, disability, gender identity or expression, marital status, national origin, genetics, race, religion, sex (including pregnancy), sexual orientation, veteran status, and family medical or genetic information.

FOR MORE INFORMATION, PLEASE CONTACT:  
David Goldenberg, MD, FACS, Chair, Department of Otolaryngology – Head and Neck Surgery  
adnippet@pennstatehealth.psu.edu or to apply online https://tinyurl.com/ycapn7jw

The Department of Otolaryngology-Head & Neck Surgery at Penn State Health Milton S. Hershey Medical Center, Penn State Children’s Hospital is seeking an additional full-time Pediatric Otolaryngologist. This is a great opportunity to join a growing team of collaborative clinical providers with the resources of one of the leading academic medical centers in the nation. The selected candidate will have the opportunity to build an airway practice should they desire.

Appointment will be at the assistant/associate/professor level. Qualified candidates must have completed an approved Otolaryngology – Head & Neck Surgery residency program, be board certified or board eligible and be fellowship trained to provide clinical and hospital-based Pediatric Otolaryngological care for our patients.

The children’s hospital sits on the campus of the Hershey Medical Center, a 548-bed Level I regional trauma center. As central Pennsylvania’s only academic medical center and home to the college of medicine, we are sought out as a resource for the most complex adult and pediatric cases. Penn State Children’s Hospital ranked among the best in the nation for the tenth consecutive year by U.S. News & World Report. Additionally, it is one of only eight hospitals in the nation to be named a Level 1 Children’s Surgery Center by the American College of Surgeons Children’s Surgery Verification Program.

FOR MORE INFORMATION, PLEASE CONTACT:

David Goldenberg, MD, FACS, Chair, Department of Otolaryngology – Head and Neck Surgery  
c/o Ashley Nippert, Physician Recruiter  
adnippet@pennstatehealth.psu.edu or to apply online https://tinyurl.com/ycapn7jw

The University of Texas Health Science Center at Houston is seeking an additional full-time Pediatric Otolaryngologist. This is a unique opportunity to join a growing team of collaborative clinical providers with the resources of one of the leading academic medical centers in the nation. The selected candidate will have the opportunity to build an airway practice should they desire.

The Department of Otolaryngology-Head & Neck Surgery at Penn State Health Milton S. Hershey Medical Center, Penn State Children’s Hospital and Penn State College of Medicine is seeking an additional full-time Pediatric Otolaryngologist. This is a great opportunity to join a growing team of collaborative clinical providers with the resources of one of the leading academic medical centers in the nation. The selected candidate will have the opportunity to build an airway practice should they desire.

Appointment will be at the assistant/associate/professor level. Qualified candidates must have completed an approved Otolaryngology – Head & Neck Surgery residency program, be board certified or board eligible and be fellowship trained to provide clinical and hospital-based Pediatric Otolaryngological care for our patients.

The children’s hospital sits on the campus of the Hershey Medical Center, a 548-bed Level I regional trauma center. As central Pennsylvania’s only academic medical center and home to the college of medicine, we are sought out as a resource for the most complex adult and pediatric cases. Penn State Children’s Hospital ranked among the best in the nation for the tenth consecutive year by U.S. News & World Report. Additionally, it is one of only eight hospitals in the nation to be named a Level 1 Children’s Surgery Center by the American College of Surgeons Children’s Surgery Verification Program.

FOR MORE INFORMATION, PLEASE CONTACT:

David Goldenberg, MD, FACS, Chair, Department of Otolaryngology – Head and Neck Surgery  
c/o Ashley Nippert, Physician Recruiter  
adnippet@pennstatehealth.psu.edu or to apply online https://tinyurl.com/ycapn7jw
The Department of Otolaryngology – Head and Neck Surgery of the University of Illinois at Chicago and the University of Illinois Hospital and Health Sciences System is seeking applicants specializing in Head and Neck Surgery:

Associate Professor/Professor in Otolaryngology

This is a full-time faculty position, at the Associate or Full Professor rank with or without tenure, commensurate with experience and interest. We are seeking someone to join our dynamic and growing clinical academic practice as part of a team-centered approach to patient care. The successful applicant should possess skills in extirpative, reconstructive, and robotic surgery, and will have academic educational as well as administrative responsibilities. This position will also function as the Head of the Division of Head and Neck Oncologic and Reconstructive Surgery, and the Director of the Head and Neck Service Line in the UIC Cancer Center.

As part of the largest medical school in the US, those interested in pursuing clinical or translational research will find a supportive infrastructure and diverse patient population.

Duties and interest to include providing direct patient care, supervising residents and medical students, and pursuing clinical or translational research. Applicants must be Board certified or eligible, and fellowship trained. For fullest consideration, application must be received by March 15, 2021. Applications will be reviewed on a rolling basis.

Interested applicants should send their curriculum vitae to:

Barry L. Wenig, MD, MPH, MBA FACS
Mario D. Mansueto Professor and Head
Department of Otolaryngology – Head and Neck Surgery (M/C 648)
University of Illinois at Chicago
1855 West Taylor Street, Room 2.42
Chicago, IL 60612
Phone: (312) 996-6582, Fax: (312) 996-1282
Email: ENTHR@uic.edu
www.otol.uic.edu

The University of Illinois at Chicago is an affirmative action, equal opportunity employer. All qualified applicants will receive consideration for employment without regard to race, color, religion, sex, national origin, protected veteran status or status as an individual with a disability. Minorities, women, veterans and individuals with disabilities are encouraged to apply.

The University of Illinois conducts background checks on all job candidates upon acceptance of contingent offer of employment. Background checks will be performed in compliance with the Fair Credit Reporting Act.
THE OHIO STATE UNIVERSITY
WEXNER MEDICAL CENTER
Department of Otolaryngology – Head and Neck Surgery

BC/BE Rhinologist

Seeking an academically productive Rhinologist for a clinician/scientist position in the Department of Otolaryngology – Head and Neck Surgery at The Ohio State University. Applicants must be board certified/board eligible, fellowship trained, and demonstrate excellence in research, teaching, patient care, and leadership. This is a tenure track position in which all ranks will be considered and leadership opportunities are available for qualified applicants. The ideal applicants must be highly motivated to set up a successful clinical or basic research effort, work well independently, and be funded or on track to submit for NIH or equivalent funding.

This is an outstanding opportunity to join one of the top ranked otolaryngology programs in the country and help us build a nationally recognized translational research effort in the field of Rhinology. We are a team-oriented department committed to a strong and vibrant research program. We offer great facilities and resources, and provide tremendous opportunity to collaborate with clinical and research faculty both in the department and across the entire college.

Located in the heart of Ohio, Columbus is the fastest growing city in the Midwest and offers a population of over 1.5 million people. Voted as one of the most livable cities in the USA, Columbus has excellent cultural, sporting, and family activities.

To build a diverse and inclusive workforce, all qualified applicants will receive consideration for employment without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, disability status or protected veteran status. The Ohio State University Wexner Medical Center is an Equal Opportunity/Affirmative Action employer.

Interested applicants should send a letter of interest and CV to:

James Rocco, MD, PhD
Professor and Chair
The Ohio State University
Department of Otolaryngology
915 Olentangy River Rd., Suite 4000
Columbus, Ohio 43212
E-mail: mark.inman@osumc.edu
Department Administrator
Or fax to: 614-293-7292
Phone: 614-293-3470

The Division of Laryngeal Surgery is seeking applicants for clinical fellowship positions. The fellowship training covers all aspects of laryngeal surgery, voice disorders, and management of the professional voice. The curriculum will provide a wide range of experiences, including phonomicrosurgery (cold instruments and lasers), laryngeal framework surgery, novel operating-room and office-based laser (Pulsed-KTP, Thulium) treatment, complex laryngeal stenosis with aortic homograft transplantation, and the use of botulinum toxin injections for spasmodic dysphonia. The fellow will participate in the management of voice disorders and clinical research as a member of a multidisciplinary team (voice scientists and speech pathologists) that has access to state-of-the-art voice clinic and surgical engineering laboratory facilities. The research fellowship provides numerous opportunities to focus on grant-funded (NIH and private foundations) clinical and basic science research projects in collaboration with interdisciplinary teams of scientists and clinicians at the Massachusetts Institute of Technology and the Wellman Laboratories of Photomedicine at the Massachusetts General Hospital. The option to collaborate with local music conservatories is also available. Qualified minority and female candidates are encouraged to apply. Send curriculum vitae and three letters of recommendation. The Massachusetts General Hospital is a teaching affiliate of Harvard Medical School.

Direct inquiries to:
Steven M. Zeitels, MD, FACS
Eugene B. Casey Professor of Laryngeal Surgery
Harvard Medical School
Director: Center for Laryngeal Surgery & Voice Rehabilitation
Massachusetts General Hospital
One Bowdoin Square, 11th Floor
Boston, MA 02114
Telephone: (617) 726-0210 Fax: (617) 726-0222
zeitels.steven@mgh.harvard.edu

A well established, busy five physician group in York, Pennsylvania is looking to add a sixth, full time Board Eligible/Board Certified Otolaryngologist. Our services include Audiology and Hearing Aid Sales. Our office has been running on an EMR system since 2006. On-Call rotation is 1:6. Initial employment includes an excellent salary and productivity bonus. Partnership offered after 1 to 2 years of employment.

York is a fast growing community with excellent schools and a very comfortable cost of living. It is convenient to Baltimore, Washington and Philadelphia.

Local inpatient hospital is well run and state-of-the-art. Surgical Center is well equipped, and partnership in the Surgical Center is available.

We are looking for a dynamic, motivated individual for partnership track. Income potential in the 90th percentile.

Contact: Renee Gohn
Office: 717-843-9089 Email: yorkent@comcast.net

York ENT associates
50th Anniversary
With more smart features to maximize staff productivity, Advantage SMART Practice® helps you deliver exceptional patient care while controlling cost.

Offering otolaryngology’s only fully customizable EHR, Advantage speeds documentation, streamlining your workflow.

**ENT’s All-In-One EHR**

- EHR
- Practice Management
- RCM
- ASC
- Patient Portal
- Online Scheduling
- Online Bill Pay
- Online Registration
- Telehealth

Ask About Our Special SMART Features

- Advantage SMART Coding® for AMA 2021 Guidelines
- Advantage SMART Workflow®
- Advantage SMART Orders®
- Advantage SMART Engagement®
- PracticeWatch® Virtual Assistant

**SCHEDULE A DEMO TODAY**

[www.compulinkadvantage.com/smart-ent](http://www.compulinkadvantage.com/smart-ent) | 805.716.8688